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The prevalence of past year injection drug use has been estimated to be 15.6 
million adults globally and 2.6 million in North America. Persons who inject drugs 
(PWID) are disproportionately burdened with a high prevalence of health and 
socioeconomic disparities and barriers to care. High rates of emergency department (ED) 
use among PWID indicate disparities in access to and use of primary care. The National 
Institute of Drug Abuse domestic research funding priorities include eliminating 
disparities in the HIV continuum of care for persons who use substances. Further, the 
National HIV/AIDS Strategy has set a goal to increase the number of PLWH with HIV 
viral suppression. While social network factors are known to influence health behaviors, 
it is not known how social networks may differ between PWID with current or former 
injection drug use and most studies do not focus on the very close ties that may be the 
most influential on health behaviors.  
 
Objectives 
The goal of this study is to characterize the social support available to PWID from 
their closest network members and determine associations of social network factors with 







We developed a social network survey to gather network characteristics among 
PWID participating in the AIDS Linked to the IntraVenous Experience (ALIVE) study in 
Baltimore, Maryland. The interviews were conducted from April 1, 2016 to June 30, 
2017. Egocentric social network data were derived from participant report about their 
network members’ attributes and relationship characteristics. Emotional, instrumental and 
informational support constructs were based on responses to seven support indicator 
questions. Latent class analysis was implemented with a multilevel approach based on the 
probabilities for each of the social support indicators. Associations with class 
membership were identified through multinomial logistic regression. The types of social 
support and the sources of support from different types of alters within ego-networks then 
became the primary exposures of interest in determining associations with emergency 
department use categorized as none, one or two or more visits in the prior six months use 




Data were available from 970 participants who completed the social network 
survey. Persons with injection drug use within the previous 12 months had smaller 
networks of close ties that were more likely to include a partner compared to persons 
with more remote injection drug use. Based on model fit statistics and in the interest of 
model interpretability and parsimony, the three-class model was selected: 1) Moderate 
support: probabilities of support were below 0.40; 2) High support: probabilities of 
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support ranged from 0.58 to 0.82; 3) Very high support: probabilities of support ranged 
from 0.91 to 0.99. Compared to moderate support, the odds of membership in the very 
high support class was greater with each increasing mean year age of alters and lower 
with less than three very close network members and each additional network member 
who ever injected drugs. Compared to the moderate class of support, greater odds of 
membership in the high support class were observed with each additional alter with daily 
contact and lower odds with each additional alter that ever used non-injection drugs. For 
the entire sample, compared to no ED visits in the prior six months, the odds of having 
one ED visit were lower for participants having informational support (AOR: 0.64; 95% 
CI: 0.41, 1.00) and the odds of two or more visits were lower for participants having a 
partner (AOR: 0.56; 95% CI: 0.35, 0.90). For PWID living with HIV, the key social 
network factor associated with HIV viral suppression was having at least one HIV-
positive alter (AOR: 2.02; 95% CI: 1.12, 3.64). 
 
Conclusions 
There were high levels of perceived support overall from the closest network ties, 
while the highest level of support was less likely with current non-injection drug use by 
participants or ever injection drug use by network members. It is both the type of support 
-- informational -- and sources of support -- partners and HIV-positive alters -- that 
represent opportunities for network level interventions that aim to improve health 
outcomes and promote optimal use of healthcare resources among PWID.   
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1.1. Injection drug use epidemiology 
Injection drug use, including subcutaneous, intramuscular and intravenous, is 
distinct from other routes of administration as it has a high potential for misuse and 
overdose resulting from rapid drug delivery and also has a greater risk for transmission of 
bloodborne infections (1). Injection drug use likely began in the 1920s and rapidly 
diffused to become the predominant route of administration for heroin (2). Opioids, 
including illegal heroin and prescription pain relievers, are the most commonly injected 
substances, followed by stimulants, including cocaine and methamphetamine (3). More 
rapid injection initiation among persons who use drugs has been observed in the era of 
prescription opioid drug misuse (4) with frequent initiation of drug use with prescription 
opioids and subsequent transition to heroin use and injection (5). 
Estimating the size of the population of persons who inject drugs (PWID) is 
challenging given the stigmatization of Injection drug use behavior (6); however, meta-
analyses reveal variations by geography and sociodemographic characteristics. The 
prevalence of past year injection drug use has been estimated to be 0.33% (15.6 million) 
of adults aged 15-64 years globally and 1.06% (2.6 million) in North America (7). 
Lifetime injection drug use in the United States has been estimated at 2.6% (6.6 million) 
of persons aged 13 years and older (8). The population proportion of persons ever having 
used injection drugs in the United States is more than double for males (3.6%) compared 
to females (1.6%), highest for white males (3.8%) followed by black males (3.4%) and 
increased with increasing age among persons aged 18 to 49 years. The prevalence of 
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injection drug use in the past year is estimated to be about 774 thousand adults and 
adolescents. As an indication of future trends, youth in Baltimore, Maryland, experience 
particularly high prevalence of injection drug use, with high school students reporting 
one of the highest levels of ever having used injection drugs of large urban school 
districts in the United States (7.2%), which is almost twice that of the Maryland statewide 
average (3.9%) (9). 
 
1.2. Health disparities  
Persons who inject drugs are disproportionately burdened with a high prevalence 
of morbidity and premature mortality. The age standardized mortality rate for PWID in 
North America is 11.19 (3.58, 18.80) (10). From 1980 through 2012, the primary causes 
of death among PWID were drug overdose and AIDS. All-cause mortality is three times 
greater among PWID living with HIV compared to HIV-negative PWID (crude mortality 
ratio: 3.15). In North America, 9.0% (230,500) of PWID are living with HIV and 55.2% 
(1.4 million) are hepatitis C virus antibody positive (3), representing 10% and 81% 
population attributable fraction to injection drug use, respectively (11). In Baltimore, 
rates of heroin overdose deaths have more than doubled from 2014 to 2016, in part due to 
the prevalence of fentanyl laced heroin (12). Persons who inject drugs also have high 
rates of sexually transmitted infections (13), tuberculosis (14), soft tissue infections (15) 
and psychiatric comorbidity (16) as well as socioeconomic disparities including high 




1.3. Healthcare use 
Active injection drug use has been associated with missed primary care visits 
(17), a 46% lower odds of receiving a primary care physical examination (18) and a 55% 
greater odds of not receiving any care compared to persons who do not use substances 
(19). Medicaid is the most common means of payment for healthcare services among 
PWID (20), and states are increasingly implementing cost controls to manage the growth 
in Medicaid payments, particularly to reduce preventable and inefficient use of healthcare 
resources (21). Persons who inject drugs at least weekly had more emergency department 
(ED) visits and hospitalizations and fewer outpatient clinic visits with an excess of 
$1,000 in healthcare costs per individual compared to persons who do not use drugs (22). 
Skin and soft tissue infections related to injection drug use are one of the most common 
reasons for an ED visit to result in a hospital admission among PWID (20) and active 
injection drug use among PWID living with HIV was associated with more frequent 
hospitalizations overall (23). With only 40% of people living with HIV infected through 
injection drug use regularly having had at least one HIV medical visit over a 4-month 
period (24), routine use of preventative services for screening, monitoring, treatment and 
prevention is low (25).  
1.4. Policy 
On the policy front, the National Institute of Drug Abuse domestic research 
funding priorities include eliminating disparities in the continuum of care for persons 
who use substances, among others, and improving HIV retention in care for difficult to 
reach populations, such as PWID (26). The Centers for Medicare and Medicaid Services 
measures ambulatory care-sensitive conditions that are potentially preventable through 
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appropriate use of primary care to adjust reimbursement for services (27), thereby 
incentivizing efforts to improve health outcomes and control costs. Further, the National 
HIV/AIDS Strategy has set a goal to increase the number of PLWH with HIV viral 
suppression and reduce HIV-related health disparities (28). With disparities in care for 
PWID infected with HIV and the increasingly recognized importance of retention in care 
both for individual health outcomes and population level HIV transmission, there is a 
need to understand the factors associated with viral suppression in this population. Most 
studies have focused on individual level predictors of health and healthcare use, some 
having incorporated social networks most commonly defined by HIV transmission risk 
behaviors. It is therefore essential to better understand the factors contributing to the 
inefficient use of more costly healthcare resources (29) and that also result in disease 
progression and ongoing transmission of HIV (30), particularly factors with the potential 
to strongly influence health and healthcare seeking behaviors, such as very close social 
network ties (31). 
 
1.5. Social networks 
Support received from social networks is known to effect decision-making about 
healthcare utilization (32). Social networks are composed of individuals’ social 
relationships (ties). Different types of social support can be seen as the personal resources 
available from these social networks/contacts (33). Social network theory’s evolution 
from the fields of sociology, social psychology and anthropology has been described by 
Scott (2004) (34). Scientists working in the Gestalt tradition posited that: groups exist in 
a social space determined by perceptions and experiences; individuals seek a balance of 
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ideas and attitudes toward people that are not in conflict; and that psychological 
wellbeing relates to social network structures created by patterns of relationships. Work 
in social anthropology supported an understanding that the content of relations and social 
roles, i.e., social network function, affects individuals in groups as well as the social 
network structure. Social learning theory suggests that individuals will model and receive 
social reinforcement for behaviors observed of significant others (35). 
 
1.5.1. Constructs from the behavioral sciences 
The following constructs represent the means by which social support can influence 
health and health behaviors (social norms, social capital and diffusion) and some of the 
underlying social processes that in part shape the structure and function of social 
networks (homophily, selection and bonding). 
• Social norms: Injunctive (what others approve/disapprove) and descriptive (what 
others appear to do) norms are a consequence of the perception of the benefits and 
costs of engaging in a particular behavior, which influences one’s own behavior (36). 
Norms are a form of social influence whereby individuals bring their behaviors and 
beliefs into alignment with that of their peers. 
• Social capital: The quantity and quality of tangible and intangible resources, actual 
and perceived, available within one’s social network that can be mobilized for a 
particular purpose (37). 
• Diffusion: The process by which disease, behaviors and ideas and are adopted and 
transferred to and within a social network (38). 
 
 6 
• Homophily: The differential tendency for people to affiliate with others like 
themselves (36). While homophily can make it difficult for new ideas and behaviors 
to take hold from outside the network, it can facilitate diffusion of ideas and 
behaviors as trust is high and interpersonal communication flows easily within 
networks of individuals having common attributes, attitudes and experiences. 
• Selection: A mechanism underlying homophily. Selecting social contacts with similar 
traits will reduce cognitive dissonance resulting from differences between an 
individual and their close social contacts (34). 
• Bonding: Benefits generated by strong close-knit ties facilitate the flow of ideas and 
resources. Individuals have fewer strong ties as they require energy to maintain and 
there are cognitive limitations to the size of a network an individual can know with 
meaningful, strong and stable ties (39). Social resources are more accessible with 
stronger ties (37). 
 
1.5.2 Social support 
Social support is the objective and subjective appraisal of an individual’s contacts 
and the resources they provide (36). Social support represents a form of social capital that 
can be accessed to meet an individual’s needs. Types of social support resources include: 
1) emotional (cultivates feelings of comfort, caring and love); 2) instrumental (materials 
and aid that solve practical problems); and 3) informational (advice, guidance and 
knowledge to help understand situations) (40). Social support is a latent construct in that 
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it cannot be observed directly, but influences measurable indicators that are believed to 
represent the latent variable of support (41). 
 
1.5.3. Egocentric networks 
Egocentric networks are first order zones, where members, known as alters, are 
directly linked to a focal person, known as the ego, and to each other (39). Each member 
represents a network node and the relationships between each ego-alter or alter-alter dyad 
are referred to as ties. Egocentric networks are also hierarchical in nature, with ego-alter 
dyads nested within the ego-network (42). A foundational use of egocentric survey and 
data analysis was the General Social Survey (43), which measured close personal ties 
using a name generator question to identify network members: “Who do you talk to about 
important matters?”. Responses were limited to five nominations. Other approaches to 
listing network members include allowing respondents to name as many as they can, then 
continuing the survey with the first alters named, which are posited to represent the 
closest and strongest ties. Egocentric data can be limited because of misperceptions of 
alters’ attitudes and behaviors. Sociometric data methods which survey other network 
members beyond the ego and represent the complete set of relations in a population gets 





1.5.4. Close network ties 
Most study of the social networks of PWID has elicited a broad list of network 
members based on a wide range of relationship roles and often HIV transmission risk 
behaviors such as sexual activity and substance use. Yet, it is the closest social ties, those 
with the strongest social bonding, that may most strongly influence health (31, 44), 
including HIV risk (45) and substance use norms (46). Close relationships provide a 
sense that the other is responsive to one’s goals, needs and desires (47, 48) and fewer 
supportive relationships may be required to meet one’s needs if they are more highly 
responsive (47). On average, Americans have four to five contacts identified as close 
based on spending time together and discussing important issues (31).  
 
1.5.5. Network stability and substance use 
While it is likely that social networks are dynamic and change over time, it is not 
known whether social network structure and function differ between persons with current 
vs. former injection drug use. There is some evidence to suggest that an individual’s 
substance use may be similar to that of their social network members (49) and that 
specific substance use behaviors are related to network composition, e.g., daily injection 
drug use frequency for persons with a lover/partner (50). It may be that the composition 
of networks differs with an individual’s own drug use status, including the number of 
network members who use substances, with complete turnover occurring following 
transition from current to former use, but overall network size may remain stable 
regardless of drug use status (51). 
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1. 6. Social networks and healthcare use and outcomes 
Among PWID, factors such as instrumental and emotional support (52), closeness 
of ties (45, 46) and norms of drug use (46) are known to influence HIV risk behaviors, 
greater use of syringe exchange programs is associated with greater use of primary care 
(53) and higher instrumental and emotional support at initiation of substance use 
treatment predicted greater retention in treatment programs (54). There is some evidence 
to suggest that emotional support, which is highly correlated with informational support 
(55), and instrumental support (56, 57) can deter or facilitate retention in outpatient care 
(56). Having network members that do not use drugs has been positively associated with 
seeking drug treatment (58). Outside of populations of PWID, it is also known that 
informational support is associated with better self-management in diabetes (59) and 
follow-up care for cancer (60), mental health (61) and heart failure (62).  
 
1.6.1. Emergency department use 
The total annual expenditures for emergency department (ED) care exceeds $60 
billion (63), yet approximately 32% of ED patients are triaged with less than urgent needs 
(64). Consequently, there may be opportunities for cost savings through more appropriate 
ED service utilization. Appropriate ED use has been operationalized as the congruence 
between the emergency care setting and the level of medical care needed in addition to 
the frequency of visits (65). Aside from medical needs, psychosocial determinants often 
underlie the frequent use of emergency care (66). While social support is known to affect 
decision-making about health care utilization in general (32), little is known regarding the 
 
 10 
relationship between social networks of PWID and the frequency of their use of ED 
services. 
People rely on information from multiple sources to make decisions regarding 
illness prevention, self-management and use of healthcare services. Information provided 
by health systems is often fragmented across providers, specializations, institutions and 
insurers (67). Because PWID have high burden of disease, they are challenged with 
finding, processing and applying medically complex information for multiple 
comorbidities. In this regard, social network members may take on an important role for 
interpreting and sharing information and giving advice. Health-related informational 
support provided by social networks is related to diagnosis, symptom interpretation and 
management, medication use, treatments, medical tests and procedures, referrals and 
advice on interactions with healthcare providers (68). Ultimately, neither the limited 
information regarding the influence of the social networks of PWID on healthcare use nor 
individual level data can entirely explain differences in use of ED services. 
 
1.6.2. HIV viral suppression 
HIV viral suppression achieved through adherence to antiretroviral treatment 
(ART) maintains immune function, controls disease progression and prevents 
transmission. The proportion of patients with an HIV diagnosis and at least one medical 
visit in the last year that were virally suppressed at the last visit is a clinic-level 
performance measure required by the US Health Resources and Services Administration 
HIV/AIDS Bureau (HRSA/HAB) for Ryan White HIV/AIDS Program grantees (69). Of 
people living with HIV that are diagnosed and in care, having a detectable viral load has 
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been related to injection drug use (70). PWID have longer time to initiating ART (71) and 
worse indicators for virologic suppression once on treatment than those who do not use 
injection drugs (72). Use of stimulants, including methamphetamine (73), crack (73, 74) 
and cocaine (73, 75) but not heroin (75) have been associated with poorer adherence to 
antiretroviral treatment (ART) compared to persons who do not use substances and 
African-American PWID have an increased risk for missed clinic visits which can lead to 
virologic failure as indicated by a detectable viral load (76). HIV-positive PWID have 
been found to have greater levels of emotional and instrumental support compared to 
HIV-negative PWID (56), but little is known about how informational support in 
particular may influence ART adherence and ultimately HIV viral suppression.  
 
1.7. Summary of gaps in knowledge 
Prior studies have shown that PWID more frequently engage in suboptimal use of 
healthcare resources for illness prevention and management as indicated by high levels of 
ED service use. Among PWID living with HIV, this can result in inadequate viral 
suppression. Most of the studies have looked at individual factors or system-level barrier 
to accessing care and some have examined social networks defined by HIV transmission 
risk behaviors rather than focusing on the ties perceived to be the most important by 
individuals, which potentially are the most influential relationships (31, 44). However, 
these factors alone cannot fully explain the variability in outcomes and the closest ties 
within the social networks of PWID in particular may provide a point of intervention for 
improving the nature of health care utilization and health outcomes in this population. In 
addition, differences in the social networks by time since last injection drug use are not 
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well defined. In order to develop interventions with social networks, we need first to 
better understand how those networks may differ for persons with current and former 
injection drug use and second which social network factors may influence health care 
utilization and health outcomes. 
1.8. Specific aims 
The goal of this study is to better understand factors that can influence suboptimal 
use of healthcare services and viral suppression among PWID, with a focus on the role of 
the closest social network ties. A more comprehensive understanding of the influence of 
social networks in healthcare seeking behaviors and outcomes will indicate important 
patient, social network and community level opportunities for intervention to support 
viral suppression and avoid potentially preventable use of costly ED services. Results 
will add to the evidence regarding disparities in care and health outcomes for a difficult 
to reach population — persons who inject drugs and are living with or at risk for HIV.  
 
Aim 1. Social support by injection drug use status 
Characterize the latent construct of social support provided by the closest, 
strongest ties among PWID and identify associations of individual and social network 
associations with latent classes of support. Of particular interest is whether social 
network characteristics and classes of support differ between persons who currently and 




Aim 2: Emergency department use and social support types and sources 
Determine if social network factors are associated with frequency of emergency 
department visits. Of special interest are the intensity, types and sources of social support 
that are related to greater or less use of ED services. 
 
Aim 3: HIV viral suppression and social support types and sources 
Determine if social network factors are associated with viral suppression among 
PWID living with HIV. Of special interest are the intensity, types and sources of social 
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2. Materials and methods 
 
2.1. Study population 
Participants were drawn from the AIDS Linked to the IntraVenous Experience 
(ALIVE) study in Baltimore, Maryland. The ALIVE study examines the epidemiology of 
adults 18 years of age or older with current and former injection drug use in two parallel 
cohorts (1). Initial recruitment began in 1988-89 followed by subsequent enrollments in 
1995, 1998, 2000, 2005-2008 and 2016. Enrollment was re-opened in September 2016 
with a goal of 600 persons being recruited for a full sample of 1,596. All community-
dwelling, non-institutionalized ALIVE participants were eligible. Because of the 
potential to alter social interactions, persons residing in nursing homes, rehabilitation 
facilities, residential drug treatment programs or others with formalized restrictions on 
their social interactions were excluded. 
 
2.2. Existing data source 
ALIVE study visits occur at the Wood Clinic building, a community-based 
research center within the Johns Hopkins Bloomberg School of Public Health and located 
in east Baltimore, Maryland. Participants provide information at semiannual ALIVE 
study visits through a combination of Audio Computer-Assisted Self-Interview (ACASI) 
for drug use behaviors and an in-person standardized interview with ALIVE study 
interviewers for health status, healthcare use and other behaviors as well as a clinical 
examination for persons living with HIV. Venipuncture is performed for serum samples 
at each study visit and sent to laboratory to obtain HIV RNA viral load and CD4+ T cell 
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counts. These data were obtained for the same visit as the one in which the interviews are 
performed for this study. 
 
2.3. Primary data collection: social network survey 
A supplemental 59-question social network module (Appendix A) was adapted 
from previously validated surveys eliciting types of social support (2, 3), health beliefs 
(4, 5) and trust in healthcare providers (6). There were 1,031 in follow up from April 1, 
2016, to June 30, 2017 who were approached, of whom 970 participants (93.5%) agreed 
to participate in the social network survey. Study interviewers administered the social 
network survey at the end of the participants’ regular 6-month follow-up study visits in a 
private room. The social network module required about 20 to 30 minutes to complete. 
Participants provided oral consent and were paid an additional $20. 
Social networks were characterized with egocentric data comprised of a focal 
individual (ego) and their social contacts (alters). Information about the network is from 
the respondent’s perspective alone. Participants reported information with the following 
prompt: “Looking back over the past 6 months, who are the people that have been 
important to you? Please think about all the people you associate with closely including 
friends, sexual partners, associates and family who are at least 13 years old or older.” The 
remainder of the social network survey focused on the first five contacts listed, here after 
referred to as the “closest ties”. We chose the first five nominations to represent the 
“closest ties” as prior studies indicated that the most important network members and are 
typically nominated first (7), the median network size among persons who use drugs has 
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been found to be four (8) and the impact on validity is minimal when limiting to five 
nominations (7). 
Social network measures included alter attributes, characteristics, relationships 
and roles as reported by the ego. To measure three different domains of social support 
(emotional, informational and instrumental), we used seven social support indicator 
questions: (1) Having someone to talk to if down; (2) Would say is in your corner; (3) 
Would pitch in to help do things; (4) Would loan over $25; (5) Would let you stay if you 
needed a place; (6) Is someone to give situation advice, and; (7) Does help you 
understand health. For each of the first 5 network members listed, egos were asked to 
report on the frequency with which each network member provided each of the seven 
specified types of support over the prior six months. Responses were recorded using a 
five-category Likert scale (1 = never; 2 = a little; 3 = sometimes; 4 = frequently; and 5 = 
always) for the seven social support indicators. Egos were also asked to describe each 
alter named with respect to demographic and behavioral characteristics and to the 
relationship with each person (i.e., duration, frequency of interaction, etc.). 
 
2.4. Social network analysis 
Twenty-nine percent of participants in ALIVE followed longitudinally were 
found to cease injecting until censoring at four years, with the remainder having one or 
more transitions between use and non-use that included about one year or more of 
cessation (9). An individual’s drug use has been related to their peers’ drug use (10) and 
persons who quit drug use over a six-month interval had significantly greater reductions 
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in the proportion of their network members who used drugs compared to persons who did 
not quit. Given the occurrence of one-year transitions between drug use and cessation and 
that the proportion of peers using drugs is different between persons who quit and did not 
quit, we defined current injection drug use as occurring within the previous year to allow 
adequate time for observation of changes in key social network characteristics. 
Social network analysis focuses on the nature of relationships among people and 
their influence on behavior and helps understand the factors associated with behavior 
change. The variables of interest are the characteristics of the egos and the alters as 
individuals as well as the ego-alter dyad relationship (tie). Summary network measures 
for egocentric data cover both structure (number, nature and type of relationships) and 
types and sources of social support provided (11). They occur at the level of the ego 
network (size, density, exposure) and the level of the dyad nested within the network (tie 
characteristics and support). Figure 1.a shows a basic egocentric network structure with 
the ego-alter dyads nested within a common ego. Figure 1.b shows various egocentric 
network configurations.  
 
2.5. Theoretical framework 
Andersen’s behavioral model is a framework for examining factors leading to 
healthcare behaviors and health outcomes (12-14). It has been used to examine healthcare 
utilization among PWID and persons living with HIV (14-16). It organizes individual, 
social and health system level factors into predisposing characteristics and enabling 
resources and needs (Figure 2). Individual characteristics that are predisposing to service 
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utilization include substance use and sociodemographic characteristics that exist before 
the occurrence of illness. Enabling tangible and intangible resources are a form of social 
capital which can be accessed through one’s social network. Structural level factors 
include community level barriers to care, such as housing and transportation, and clinic 





2.5. References  
1. Vlahov D, Anthony JC, Munoz A, Margolick J, Nelson KE, Celentano DD, et al. 
The ALIVE study, a longitudinal study of HIV-1 infection in intravenous drug users: 
description of methods and characteristics of participants. NIDA Res Monogr. 
1991;109:75-100. 
2. Sherbourne CD, Stewart AL. The MOS social support survey. Social science & 
medicine (1982). 1991;32(6):705-14. 
3. Latkin C. The Impact of Neighborhoods, Networks, and Depression on Drug 
Users’ HIV Risk. 2009. 
4. RAND Corporation. Medical Outcomes Study: 36-Item Short Form Survey 
Instrument 2009 [Available from: 
http://www.rand.org/health/surveys_tools/mos/mos_core_36item_survey.html. 
5. Bellon JA, Delgado A, Luna JD, Lardelli P. Psychosocial and health belief 
variables associated with frequent attendance in primary care. Psychological medicine. 
1999;29(6):1347-57. 
6. Ommen O, Thuem S, Pfaff H, Janssen C. The relationship between social support, 
shared decision-making and patient's trust in doctors: a cross-sectional survey of 2,197 
inpatients using the Cologne Patient Questionnaire. International journal of public health. 
2011;56(3):319-27. 
7. Merluzzi J, Burt RS. How many names are enough? Identifying network effects 
with the least set of listed contacts. Social Networks. 2013;35(3):331-7. 
 
 30 
8. Latkin CA, Knowlton AR, Forman VL, Hoover DR, Schroeder JR, Hachey M, et 
al. Injection Drug Users' Disclosure of HIV Seropositive Status to Network Members. 
AIDS and Behavior. 2001;5(4):297-305. 
9. Galai N. Longitudinal Patterns of Drug Injection Behavior in the ALIVE Study 
Cohort,1988-2000: Description and Determinants. American Journal of Epidemiology. 
2003;158(7):695-704. 
10. Latkin CA, Knowlton AR, Hoover D, Mandell W. Drug network characteristics 
as a predictor of cessation of drug use among adult injection drug users: a prospective 
study. The American journal of drug and alcohol abuse. 1999;25(3):463-73. 
11. Valente TW. Social networks and health. Oxford, New York: Oxford University 
Press, Inc.; 2010. 
12. Andersen RM. Revisiting the behavioral model and access to medical care: does it 
matter? Journal of health and social behavior. 1995;36(1):1-10. 
13. Brennan A, Morley D, O'Leary AC, Bergin CJ, Horgan M. Determinants of HIV 
outpatient service utilization: a systematic review. AIDS Behav. 2015;19(1):104-19. 
14. Mkanta WN, Uphold CR. Theoretical and methodological issues in conducting 
research related to health care utilization among individuals with HIV infection. AIDS 
patient care and STDs. 2006;20(4):293-303. 
15. Mizuno Y, Wilkinson JD, Santibanez S, Dawson Rose C, Knowlton A, Handley 
K, et al. Correlates of health care utilization among HIV-seropositive injection drug 
users. AIDS Care. 2006;18(5):417-25. 
16. Kilbourne AM, Andersen RM, Asch S, Nakazono T, Crystal S, Stein M, et al. 
Response to symptoms among a U.S. national probability sample of adults infected with 
 
 31 
human immunodeficiency virus. Medical care research and review : MCRR. 
2002;59(1):36-58. 
17. Knowlton AR, Hoover DR, Chung S-e, Celentano DD, Vlahov D, Latkin CA. 
Access to medical care and service utilization among injection drug users with 
HIV/AIDS. Drug and alcohol dependence. 2001;64(1):55-62. 
18. Wilkinson JD, Zhao W, Arnsten JH, Knowlton AR, Mizuno Y, Shade SB, et al. 
Longitudinal correlates of health care-seeking behaviors among HIV-seropositive 
injection drug users: how can we intervene to improve health care utilization? Journal of 
acquired immune deficiency syndromes (1999). 2007;46 Suppl 2:S120-6. 
19. Crossley N, Bellotti E, Edwards G, Everett MG, Koskinen J, Tranmer M. Social 












Figure 1. Egocentric networks. 
a) Ties nested with an ego-network; b) Various network configurations. Adapted from 













Figure 2. Andersen’s behavioral model of health care use.  
With key exposures (injection drug use and social networks) and outcomes (emergency 




3. Social networks and latent classes of social support comparing persons with 
current to former injection drug use 
 
3.1. Abstract 
Little is known about the differences in the composition of social networks and 
types of social support available to persons who currently inject drugs compared to those 
with remote injection drug use. A better understanding of how support networks may 
change as individual patterns of injection drug use change may help tailor more effective 
social network interventions to promote health. The aim of this study is to examine social 
support provided by close network ties among persons who inject drugs and identify 
differences in support by time since last injection drug use.  
Information was obtained from a sample of AIDS Linked to the IntraVenous 
Experience study participants at their six-month study visit from April 1, 2016 through 
June 30, 2017. A multilevel latent class analysis clustered on individual ego-networks 
was performed to identify underlying latent constructs of social support using seven 
support indicators. Multinomial logistic regression was used to examine the associations 
of the ego and network variables with latent class membership. 
Of the 970 ALIVE participants who completed the supplemental social support 
survey, 34.1% reported that they last injected drugs in the previous twelve months. 
Persons with injection drug use in the previous 12 months were more likely to have 
smaller networks of close ties that included a partner. Based on model fit statistics and in 
the interest of model interpretability and parsimony, the three-class model was selected: 
1) Moderate support: probabilities of support were below 0.40; 2) High support: 
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probabilities of support ranged from 0.58 to 0.82; 3) Very high support: probabilities of 
support ranged from 0.91 to 0.99.  
In adjusted analysis, compared to the moderate support class, greater odds of 
membership in the high support class was associated with each increasing mean year age 
of alters (AOR: 1.03; 95% CI: 1.01, 1.05) and each additional alter with daily contact 
(AOR: 1.33; 95% CI: 1.14, 1.56). Lower odds of membership in the high support class 
was associated with each additional alter that ever used non-injection drugs (AOR: 0.81; 
95% CI: 0.69, 0.95). Compared to the moderate support class, greater odds of 
membership in the very high support class was associated with each increasing mean year 
age of alters (AOR: 1.03; 95% CI: 1.01, 1.05) and each additional alter with daily contact 
(AOR: 1.54; 95% CI: 1.30, 1.83). Lower odds of membership in the very high support 
class was associated with non-injection drug use in the past year (AOR: 0.58; 95% CI: 
0.37, 0.92), less than three very close network members (AOR: 0.50; 95% CI: 0.29, 0.85) 
and each additional network member who ever injected drugs (AOR: 0.75; 95% 0.56, 
1.00) and always argued with (AOR: 0.59; 95% CI: 0.44, 0.78).  
Results showing high levels of perceived closeness and support overall suggest a 
potentially impactful resource for positively influencing health through social network 
interventions. Given that network members are able to influence social norms and the 
closest relationships are potentially the most influential, health promotion interventions 
that focus on the small core of long-standing and very close ties, particularly relatives and 





The social networks of persons who inject drugs (PWID) are known to influence 
drug use and sexual risk behavior norms, including exchanging sex for drugs (1), sharing 
needles (2) and frequency of injection (3) among others. Because injection and other drug 
use is associated with high rates of sexually transmitted infections, viral hepatitis, HIV (4, 
5), tuberculosis (6), soft tissue infections (7) and depression (8, 9), PWID must navigate 
healthcare systems to meet multiple complex health needs. There is evidence to suggest 
that emotional support, which is highly correlated with informational support (10), 
financial and instrumental support can facilitate retention in outpatient care for PWID 
living with HIV (11, 12). Conversely, it has also been found that network members may 
be less likely to provide emotional and more likely to provide material support for PWID 
living with HIV or hepatitis C (13). 
A substantial proportion of PWID have been found to cease injecting or have 
multiple transitions between use and non-use over time (14, 15), but little is known about 
differences in the composition of social support networks and the domains of social 
support provided between these groups. A better understanding of how support networks 
may change as individual patterns and frequency of drug use change may be relevant for 
both maintaining drug use cessation as well as other positive health behaviors. There is 
some evidence of complete turnover of network members occurring when people 
transition from current to former use, but overall network size may remain stable 
regardless of drug use status (16). Substance use by social contacts may be related to an 
individual’s own substance use (17), and having network members that do not use drugs 
has been positively associated with seeking treatment (18). While higher instrumental and 
 
 36 
emotional support at initiation of substance use treatment predicted greater retention in 
care, it was not protective against stressful conditions that increase the risk of relapse 
over the long term (19). 
There is limited understanding of how social networks differ for persons who are 
currently injecting and those who have stopped injecting. In addition, studies typically 
define support networks broadly grouping together persons who provide different 
domains of social support and at varying levels of influence. Consequently, interventions 
leveraging social support may be missing opportunities to promote optimal health 
behaviors and outcomes by not focusing on the smaller set of very close ties that are more 
likely to influence health behaviors (20) and without consideration of the differences in 
the social networks of current and former injection drug users.  
This study aims to address these gaps by (1) examining social support as a latent 
construct provided by closer/stronger relationships among persons who inject drugs 
(PWID) and (2) determining whether social support networks differ between persons who 
currently and formerly injected drugs. The latent types of social support from the most 
important personal network ties are described with respect to different domains of social 
support. We hypothesized that the highest level of social support would be found among 
those not currently injecting drugs, with chronic health conditions and a greater number 
of very close ties with network members. A better understanding of how support 
networks may change as individual patterns and frequency of drug use change may be 






This study was an analysis of cross-sectional survey data from the AIDS Linked 
to the IntraVenous Experience (ALIVE) study. The ALIVE study is a longitudinal cohort 
which examines the epidemiology of injection drug use and associated health factors 
among adults 18 years of age or older with a history of injection drug use (21). ALIVE 
participants completed standardized questionnaires, Audio Computer-Assisted Self-
Interview (ACASI), in-person interviews and provided bio-specimens for behavioral, 
socioeconomic and clinical parameters at 6-month visits. As described previously, a 
supplemental 59-question social network survey module was developed and used to 
gather information from participants about the attributes of their social network members, 
the nature of their relationships and the support they are available to provide. Data in this 
study are from 970 ALIVE participants who completed the supplemental social support 
survey in the from April 1, 2016, to June 30, 2017. 
3.3.1. Variables 
Social network measures included characterization of participant and network 
member relationship ties. The Likert scale responses for frequency that each network 
member provided emotional, informational and instrumental support (1 = never; 2 = a 
little; 3 = sometimes; 4 = frequently; and 5 = always) over the prior six months for seven 
social support indicators were collapsed from five to three by combining ‘never’ with ‘a 
little’ and ‘sometimes’ with ‘frequently’. This approach had several advantages for the 
interpretation and analysis of our data. First, the proportion of ‘always’ responses was 
high, ranging from 62% to 76%. Second, the Likert data are assumed to be 
nonparametric, the scale items do not represent equal intervals and collapsing these items 
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may minimize ambiguity due to participants misjudging the intensity of an inherently 
subjective response. Third, keeping all five items on the scale resulted in a large number 
of parameters and a sparse distribution of some item rating scores.  
Additional variables were generated to describe network structure and function. A 
binary variable for frequency of interaction at least daily compared to less than daily was 
created from responses for talking with network members daily, weekly, monthly or 
greater than monthly. Binary variables for relationship quality were created for: trust with 
life based on a scale from 1) no trust to 5) trust with life; very close vs not very close 
based on a scale from a 1) not very close to 5) very close; and frequently to always vs 
less than frequently argue from a scale of 1) never to 5) always argue. Network density 
was defined as the number of social ties within a network that know each other as a 
proportion of all possible ties. Multiplexity was defined by the number of different social 
support roles, represented by the seven indicators, provided by network members. 
Homophily between ego and network member characteristics was determined for the 
same: race; gender; 10-year age category; 6-month and ever injection drug use; non-
injection drug use; and HIV status. 
Variables for health status were defined through self-report for medical 
comorbidities including diabetes mellitus, hypertension, heart disease, cardiovascular 
disease, stroke, and renal disease. Depression was confirmed through administration of 
the Center for Epidemiological Studies-Depression (CESD) with cut off of 22 selected 
given that persons with history of opioid misuse score higher than the general population 
(22). HIV status was confirmed through enzyme-linked immunosorbent assay and 
confirmed through Western blot. Chronic hepatitis C infection was defined as ever 
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having had a positive anti-hepatitis C virus antibody test and detectable hepatitis C viral 
RNA measured through a study visit.  
 
3.3.2. Statistical analysis 
Descriptive statistics were used to compare participant demographics, substance 
use and social networks across a binary variable of most recent injection drug use by 
participants within or greater than the last 12 months prior to the study visit using T tests 
for continuous and chi-square tests for categorical measures. The tests of significance for 
comparisons of social network characteristics were adjusted for correlations within 
individual networks by clustering on network members. Based on the literature on drug 
use social networks, we defined current injection drug use as occurring within the 
previous year to allow adequate time for observation of changes in key social network 
characteristics. 
Egocentric networks can be conceptualized at multiple levels: the tie or 
relationship between the ego and network member, referred to as level 1 variables, and 
attributes aggregated across the personal network for a particular ego, referred to as level 
2 variables (23). We used information about support from the network member-ego dyad 
relationship level to identify latent classes of social support rather than relying on a 
summary variable that aggregates support at the level of the individual. 
A key analysis concern was to determine if the latent construct of social support 
occurred within personal networks at the level of the participant-network member tie or 
the level between participants’ personal networks. To answer this question, we examined 
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the intra class coefficient (ICC) to determine the proportion of total variance in social 
support that can be attributed to ego-network member dyads without regard for clustering 
on the individual ego network compared to the variance in social support between ego-
networks that accounts for the nesting of network members within the social network of 
the same ego. The ICC was calculated as between variance divided by total variance: ρ = 
σ2between / (σ2between +σ2within). We found that the social support received from 
network members who shared the same ego was more similar than those who did not. 
Therefore, the latent class analysis (LCA) was implemented with a multilevel approach 
that used social support indicators from the level of each ego-network member tie to 
identify latent classes of social support received at the level of the participant. 
A multilevel latent class analysis clustered on individual ego-networks was 
performed to identify the underlying, unobservable constructs of social support to take 
into account the level of social support between egos, the influence of each network 
member and the interdependence of social support measures nested within personal 
networks. Latent class analysis is a person-centered, data reduction approach that clusters 
individuals who are more similar to each other based on observed patterns of categorical 
indicators (24). Latent class analysis has been used to identify subgroups with different 
levels and types of perceived informational, instrumental and emotional support provided 
by network members (25). Among PWID, LCA has been used to identify latent groups of 
substance use and other health risk behaviors (26-31).  
A series of models with increasing number of latent classes were run to compare 
solutions and identify the number of classes that best described the data using the 
collapsed 3-item responses for each of the seven social support indicators. The model 
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with the optimal number of classes was determined by iteratively specifying an additional 
class starting with two and comparing measures of fit for: Akaike’s Information Criteria; 
sample size adjusted Bayesian Information Criteria; the Lo-Mendell Rubin adjusted 
likelihood ratio test for n versus n-1 classes; entropy, which indicates the separation of 
the latent classes; and interpretability of the results. Latent class analysis was executed 
using MPlus version 8.0 (Muthèn and Muthèn) and class assignment was based on the 
most likely class. The classes in the final model were regressed on a number of individual 
and social network variables using multinomial regression to examine the associations of 
the ego and network variables. Social network variables used the count of network 
members with a given attribute. Variables with significant associations with class 
membership (p≤0.05) were included in the final multivariable model. Latent class 
membership and regression analysis were performed using Stata version 15.0 (StataCorp, 
College Station, TX). 
 
3.4. Results 
Of the 970 ALIVE participants who completed the supplemental social support 
survey (Table 3.1.), 596 reported that they last injected drugs more than 12 months prior 
to the study (61.4% defined as former PWID) and 374 reported injecting within 12 
months (38.6% defined as current PWID). Of those injecting in the last 12 months, 287 
(76.7%) had injected in the previous 6 months. Compared to persons without recent 
injection drug use, those who have used injection drugs in the last 12 months were 
younger (median age 53 yrs. vs. 57 yrs.; p<0.001) and were less likely to identify as black 
(76.5% vs. 91.9%; p<0.001) or be HIV-positive (24.3% vs. 34.1%; p=0.001). They were 
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more likely to: report homelessness in the prior 6 months (19.0% vs. 5.0%; p<0.001); 
have 6-month income <$5,000 (74.9% vs. 58.9%; p<0.001); be hepatitis C positive with 
confirmed hepatitis C RNA (61.9% vs. 52.1%; p=0.003); have depressive symptoms 
(38.0% vs. 17.3%; p<0.001); and live alone (34.0% vs. 40.8%; p=0.036). Persons with 
12-month injection drug use were significantly more likely (p<0.001) to use non-
injection drugs and to be active in a substance use support group in the prior 6 months 
(49.5% vs. 40.7%; p=0.007). 
Persons with 12-month injection drug use had a smaller median network size (3 
vs 4; p=0.015), were less likely to have a least one black network member (81.8% vs. 
94.4%; p<0.001) and more likely to have a spouse/partner (47.1% vs. 39.5%; p=0.024) 
(Table 3.2.). Although the difference in having one or more network members reported as 
very close did not vary by current injection drug use status, the mean score of closeness 
with social ties was significantly lower for networks with 4-5 vs 1-3 members (4.59 vs. 
4.70; p=0.005). Measures of homophily among the total 3,388 participant-network 
member ties indicated that for persons with injection drug use in the previous 12 months 
compared to greater than 12-months, characteristics were more dissimilar between egos 
and alters for sex, race, six-month inject drug use and ever street drug and more similar 
for 10-year age, HIV status and ever injection drug use (Supplemental Table S.3.1.). For 
injection drug use in the previous 12 months compared to greater than 12 months, the 
highest homophily was seen for race (94.1% vs. 96.1%; p=0.006) and the lowest for ever 
injection drug use (20.9% vs. 13.7%; p<0.001). 
Social support across the three collapsed levels for each indicator are stratified by 
participant network size and time since last injection drug use for the 3,388 participant-
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network member ties (Table 3.3.). For smaller networks (0-3 alters), persons with 12-
month compared to greater than 12-month injection drug use had a smaller proportion of 
network members that always provided emotional support (in your corner: 72.3% vs. 
80.7%, p=0.018); instrumental support (pitch in: 63.3% vs. 73.6%, p=0.026; loan money: 
55.0% vs. 71.6%, p=0.002; place to stay: 64.6% vs. 75.5%, p=0.005). For larger 
networks (4-5 alters), persons with 12-month injection drug use similarly had a smaller 
proportion always providing emotional support (in your corner: 68.2% vs. 78.8%; 
p=0.001); instrumental support (pitch in: 57.0 vs. 69.8%, p=0.001; loan money: 51.6% 
vs. 65.7%, p<0.001; place to stay: 60.3% vs. 72.4%, p=0.001) and informational support 
(situational advice: 58.4% vs. 67.5%, p=0.013). 
Multiplexity for network members always providing support for all seven of the 
support indicators was smaller for persons with 12-month compared to greater than 12-
month injection drug use (29.4% vs. 37.3%) and greater for providing no support (14.3% 
vs. 9%) (Supplemental Table S.3.2). Overall, provision of six to seven indicators of 
support was highest for partners (63%) followed by women (52.6%), relatives (51.4%), 
men (44.3%) and least for friends (36.8%). 
 
3.4.1. Latent classes of social support 
Results of the latent class analysis model comparing results from two to five class 
models is reported in Table 3.4. Entropy was good for all solutions, with higher values 
indicating clear separation of classes. While the AIC and sample size adjusted BIC were 
lowest for the five-class model, the Lo-Mendell Rubin adjusted likelihood ratio test 
(LMR) showed no insignificant improvement in model fit going from a three to four class 
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solution. Based on the LMR and in the interest of model interpretability and parsimony, 
the three-class model was selected. 
Figures 3.1. to 3.3. illustrate the conditional probabilities of participant class 
membership and the class prevalence based on the estimated posterior probabilities of 
response level for each of the seven indicators of social support. We defined these three 
groups as moderate, high and very high with the middle level of high support being the 
reference for subsequent analyses. 
Moderate support: The probabilities of network members always providing any 
social support was below 0.40 for all indicators. However, the probabilities of providing a 
moderate level of support, denoted as sometimes-frequently, was over 0.50 for having 
someone to talk to, always being in your corner, pitching in and giving general advice.  
High support: The probability of network members always providing support for 
each of the seven indicators ranged from 0.58 to 0.82, followed by sometimes-frequently 
from 0.158 to 0.31 and none-a little from 0.02 to 0.11.  
Very high support: The probabilities for alters always providing support for each 
of the seven indicators was very high, ranging from 0.91 to 0.99. Probabilities for 
sometimes-frequently and none-a little were below 0.05 for both. 
 
3.4.2. Associations with social support class membership 
Table 3.5. shows results of the multinomial regression of the associations with 
latent class membership using the middle class of support, labeled high, as the base for 
comparisons with the moderate and very high support classes. In multivariable analysis, 
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compared to the moderate support class, greater odds of membership in the high support 
class was associated with each increasing mean year age of alters (AOR: 1.03; 95% CI: 
1.01, 1.05), each additional alter with daily contact (AOR: 1.33; 95% CI: 1.14, 1.56) and 
having someone to do something enjoyable with (AOR: 3.24; 95% CI: 2.20, 4.78). 
Compared to moderate support, lower odds of membership in the high support class was 
associated with each additional alter that ever used non-injection drugs (AOR: 0.81; 95% 
CI: 0.69, 0.95). Compared to the moderate support class, greater odds of membership in 
the very high support class was associated with each increasing mean year age of alters 
(AOR: 1.03; 95% CI: 1.01, 1.05) and having someone to do something enjoyable with 
(AOR: 7.74; 95% CI: 4.87, 12.30). Compared to the moderate support class, lower odds 
of membership in the very high support class was associated with non-injection drug use 
in the past year (AOR: 0.58; 95% CI: 0.37, 0.92), less than 3 very close network 
members (AOR: 0.50; 95% CI: 0.29, 0.85) and each additional network member who 
ever injected drugs (AOR: 0.75; 95% CI: 0.56, 1.00) or used non-injection drugs (AOR: 
0.60; 95% 0.49, 0.73) and always argued with (AOR: 0.59; 95% CI: 0.44, 0.78). 
 
3.5. Discussion 
This study describes three latent classes of social support and associations with 
participant and social network attributes among a cohort of persons with current and 
former injection drug use. The overall study population characteristics are similar to 
national data indicating that persons with 12-month injection drug use are younger, more 
often white and experience a range of socioeconomic and health disparities including 
homelessness, low income, chronic hepatitis C and HIV (32-34). We also found persons 
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with 12-month injection drug use to be more likely to live alone, have smaller networks 
and be more likely to have a partner/spouse. However, density, age, gender, HIV or HCV 
status, frequency of contact, trust, closeness and conflict were not significantly different 
by injection drug use status. While there were differences between individual indicators 
of support and injection drug use by alters was associated with lower likelihood of having 
very high support, participant injection drug use in the past 12 months was not associated 
with latent classes of support. 
As expected, the highest level of support was associated with having a greater 
number of close ties with network members. Participants in the very high support group 
were significantly less likely to use non-injection drugs or have network members that 
ever-used non-injection drugs. Differential association theory suggests that peers are 
likely to share similar substance use behaviors (35), and we did find that a large 
proportion of former injectors shared similar non-injection substance use behaviors with 
their network members; however, homophily of injection drug use was low for current or 
former injectors and their network members. Substance use by friends has been 
associated with low or no support in communities with a high prevalence of substance 
use (36). For a population of PWID, having close network members that do not use drugs 
might be considered a form of social capital and promote adoption of norms that 
discourage substance use (35) and HIV and hepatitis C infection risk behaviors such as 
needle sharing and condomless sex (1, 37).  
In the very high support group, there was strong separation between network 
members always providing support for each indicator compared to none to a little or 
sometimes to frequently providing support. For the high class of support, the probabilities 
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of network members always providing support were highest for emotional and lowest for 
financial support and health advice. This class can be further described as high support 
with an emphasis on emotional support. The lowest levels of support were observed in 
the moderate class, where the greatest probabilities were for network members providing 
help with a situation by pitching in, with low probabilities of emotional support and 
situational advice. This class might be described as moderate support with an emphasis 
on instrumental help. 
All three latent classes represented relatively high levels of support, which 
coincides with our focus on the closest social ties when eliciting network members rather 
than characterization across a broad range of relationship roles. This level of high support 
is in agreement with a similar approach used to delineate social networks for up to five of 
the most important people spoken to in the prior month and measures of the quantity 
(number of alters providing support) and quality (frequency of contact and proximity) to 
identify latent classes of support that found most (59%) were classified in the high 
support group and most had at least one person available to provide emotional, 
instrumental and informational support (38).  
Although perceived closeness was high regardless of network size, it was lower in 
larger networks, with members of smaller networks more likely to always provide 
emotional, instrumental and informational support, similar to findings that average 
closeness decreases with increasing numbers of close contacts and an increasing total 
number of social ties weakens the average strength of those ties overall (20). The 
capacity for close, responsive relationships may be a finite resource that limits the 
number of very close relationships possible within personal networks. Further supporting 
 
 48 
the generally high closeness with network members is the long median relationship 
duration, which agrees with the high proportion of network members that are relatives 
and partners and suggests that these well-established relationships remain important 
across networks of current and former PWID. Relatives are particularly important in the 
social networks of African-Americans, indicated by greater contact with family members 
compared to whites who are more likely to receive support from friends (39). We found a 
greater proportion of partners, women and relatives always provided six to seven 
domains of support compared to men and friends. There may be overlap of the high level 
of support from women and partners as over two-thirds of partners were women.  
A high degree of social connection and interaction is indicated by the large 
proportion of participants with high levels of trust and closeness and the associations of 
daily contact, shared leisure activities and conflict with levels of social support. 
Participants in the very high support group had a lower likelihood of conflict with their 
social ties. Negative social interactions include criticism, invading privacy, interfering in 
affairs among others (40), and have been associated with lower health-related quality of 
life (41). Some individuals have a negative orientation toward accessing their social 
resources when experiencing health problems, which may be mediated by negative social 
interactions with peers (42). Cohesive, non-conflictive family relationships and 
instrumental and emotional support have been highly correlated with medical treatment 
adherence (43), which may be particularly important for this population with a high 
degree of multi-comorbidity. It was not surprising that having someone to do something 
enjoyable with was associated with greater odds of membership in the very high and 
lower odds of membership in the moderate support group. It has been suggested that one 
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means by which social support is positively associated with better health is through lower 
loneliness, which can result from participation in leisure and recreational activities (44). 
3.6. Limitations 
Although our study was limited to the most important five network members, 
keeping the network to five may not be a substantial limitation given that previous work 
in a similar population found the mean size of the social support network to be about 5 
(45) and the number of network members providing health advice was 2.9 and financial 
support 2.7 (46). Social desirability may have resulted in participants reporting greater 
levels of support than actually exist. This is a cross sectional study and we were unable to 
determine the effect of cessation of injection drug use on social network composition and 
support. While there was limited variability of social support across the five-level Likert 
scale, the predominance of network members ‘always’ providing support is not surprising 
given the name generator aimed to elicit the most important, closest network ties and 
indicates that respondents in general perceived a clear distinction between ‘always’ and 
the remaining options. 
 
3.7. Conclusion 
These findings shed light on the nature of the core social support network among 
PWID. It was encouraging that this sometimes-disenfranchised population had relatively 
high levels of support across the seven support indicators for informational, instrumental 
and emotional support among a network of the closest most important ties. Results 
showing high levels of perceived closeness and support overall suggest a potentially 
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impactful resource for positively influencing health through social network interventions. 
Given that network members are able to influence social norms, for example, by 
discussing or modeling particular health behaviors (47), and the closest relationships are 
potentially the most influential (20, 48), health promotion interventions that focus on the 
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Characteristic N (%) N (%) N (%) p value 
Age, median (IQR) 56 (50-60) 57 (52-61) 53 (45-58) <0.001 
Female 315 (32.5) 201 (33.7) 114 (30.5) 0.29 
Black 834 (86.0) 548 (91.9) 286 (76.5) <0.001 
Any homelessness 1 101 (10.4) 30 (5.0) 71 (19.0) <0.001 
Income <$5, 0001 626 (65.1) 346 (58.9) 280 (74.9) <0.001 
HIV-positive  294 (30.3) 203 (34.1) 91 (24.3) 0.001 
Hepatitis C positive 2 535 (55.9) 306 (52.1) 229 (61.9) 0.003 
Number of comorbidities 3     
0 311 (32.1) 165 (27.7) 146 (39.0) <0.001 
1 286 (29.5) 171 (28.7) 115 (30.7)   
≥2 373 (38.5) 260 (43.6) 113 (30.2)   
CESD>224 245 (25.3) 103 (17.3) 142 (38.0) <0.001 
Live alone 1 370 (38.2) 243 (40.8) 127 (34.0) 0.036 
 
Substance use 
    
6 mo. injection drug use 1     
Inject heroin 176 (18.1) -- 176 (47.1) -- 
Inject cocaine 100 (10.3) -- 100 (26.7) -- 
Inject speedball 139 (14.3) -- 139 (37.2) -- 
Inject other 10 (1.0) -- 10 (2.7) -- 
Injection freq. (1 mo.)     
None 681 (70.4) -- 86 (23.1)  
<Daily 158 (16.3) -- 158 (42.4)   
Daily 129 (13.3) -- 129 (34.6)   
Crack cocaine 1 243 (25.1) 81 (13.6) 162 (43.3) <0.001 
Opioid replacement therapy 1 478 (49.3) 229 (38.4) 249 (66.6) <0.001 
Sedative/tranq., street 1 85 (8.8) 25 (4.2) 60 (16.0) <0.001 
Painkiller, street 1 61 (6.3) 14 (2.3) 47 (12.6) <0.001 
Marijuana 1 155 (16.0) 65 (10.9) 90 (24.1) <0.001 
Alcohol, daily 1 36 (3.7) 13 (2.2) 23 (6.1)  <0.001 
Substance use support grp. 1 426 (44.1) 242 (40.7) 184 (49.5) 0.007 
IDU=injection drug use; IQR=interquartile range 
1 Last 6 months 
2 Detectable Hepatitis C RNA 
3 HIV, diabetes mellitus, hypertension, heart disease, cardiovascular disease, stroke, renal 
disease, respiratory disease, seizure disorder, dyslipidemia 













Characteristic N (%) N (%) N (%) p value 
Network size, median 
(IQR) 
4 (2-5) 4 (2-5) 3 (2-5) 0.015 
Density, mean (SD) 0.99 (0.08) 0.98 (0.09) 0.99 (0.08) 0.94 
Age, median (IQR) 54 (42-63) 54 (43-63) 54 (41-62) 0.70 
Female 1 891 (92.7) 548 (92.9) 343 (92.5) 0.80 
Black 1 867 (89.6) 561 (94.4) 306 (81.8) <0.001 
HIV-positive 1 122 (12.8) 71 (12.1) 51 (13.8) 0.46 
Hepatitis C positive 1 210 (22.4) 117 (20.4) 93 (25.5) 0.066 
 
Relational 
    
Partner/spouse 1 409 (42.2) 232 (38.9) 177 (47.3) 0.010 
Friend 1 453 (46.7) 275 (46.1) 178 (47.6) 0.66 
Relative1  848 (87.4) 523 (87.8) 325 (86.9) 0.70 
Professional 1 23 (2.4) 15 (2.5) 8 (2.1) 0.71 
Years known, median 
(IQR) 
32 (23-42) 34 (24-43) 31 (20-41) 0.009 
Frequency of contact 1, 2 850 (87.6) 531 (89.1) 319 (85.3) 0.080 
Trust 1, 3 913 (94.2) 567 (95.3) 346 (92.5) 0.071 
Closeness 1, 4 894 (93.3) 560 (94.6) 334 (91.3) 0.044 
Do you argue with 1, 5 283 (29.2) 175 (29.4) 108 (29.0) 0.91 
IDU=injection drug use; IQR=interquartile range 
1 One or more network members 
2 At least daily 
3 Trust with life, on a scale from 1=Don’t trust to 5=Trust with life 
4 Very close, on a scale from 1=Not very close to 5=Very close 
5 Frequently-always, on a scale from 1=Never to 5=Always 
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Table 3.3. Social support indicators by time since last injection drug use stratified by network size for ego-alter dyad. 
















p-value Support indicator N (%) N (%) N (%) N (%) N (%) 
Emotional        
Could talk to if down        
Never-a little 291 (8.6) 36 (5.9) 28 (6.3) 0.176 139 (9.1) 88 (10.8) 0.095 
Sometimes-frequently 923 (27.3) 149 (24.6) 136 (30.6)  390 (25.6) 248 (30.5)  
Always 2170 (64.1) 421 (69.5) 280 (63.1)  992 (65.2) 477 (58.7)  
Would say is in your corner        
Never-a little 127 (3.8) 16 (2.6) 19 (4.3) 0.018 49 (3.2) 43 (5.3) 0.001 
Sometimes-frequently 690 (20.5) 101 (16.7) 103 (23.4)  272 (18.0) 214 (26.5)  
Always 2550 (75.7) 489 (80.7) 319 (72.3)  1190 (78.8) 552 (68.2)  
 
Instrumental 
       
Would pitch in to help do things        
Never-a little 198 (5.9) 27 (4.4) 22 (5.0) 0.026 76 (5.0) 73 (9.0) <0.001 
Sometimes-frequently 931 (27.6) 134 (22.0) 141 (31.8)  381 (25.2) 275 (34.0)  
Always 2245 (66.5) 448 (73.6) 281 (63.3)  1055 (69.8) 461 (57.0)  
Would loan over $25        
Never-a little 407 (12.0) 62 (10.2) 51 (11.5) 0.002 150 (9.9) 144 (17.8) <0.001 
Sometimes-frequently 878 (26.0) 110 (18.2) 148 (33.5)  372 (24.5) 248 (30.6)  
Always 2093 (62.0) 434 (71.6) 243 (55.0)  998 (65.7) 418 (51.6)  
Would let stay if needed a place        
Never-a little 409 (12.1) 60 (9.9) 65 (14.7) 0.005 159 (10.5) 125 (15.4) 0.001 
Sometimes-frequently 638 (18.9) 89 (14.6) 92 (20.8)  260 (17.1) 197 (24.3)  
Always 2337 (69.1) 460 (75.5) 286 (64.6)  1101 (72.4) 490 (60.3)  
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Table 3.3. continued.        














Support indicator N (%) N (%) N (%) p-value N (%) N (%) p-value 
Informational        
Someone to give situation advice        
Never-a little 232 (6.8) 27 (4.4) 19 (4.3) 0.193 107 (7.0) 79 (9.7) <0.013 
Sometimes-frequently 920 (27.2) 142 (23.3) 132 (29.7)  387 (25.4) 259 (31.9)  
Always 2236 (66.0) 441 (72.3) 293 (66.0)  1027 (67.5) 475 (58.4)  
Does help understand health        
Never-a little 510 (15.2) 82 (13.5) 70 (15.8) 0.141 213 (14.1) 145 (18.1) 0.066 
Sometimes-frequently 907 (27.0) 140 (23.1) 122 (27.6)  406 (26.9) 239 (29.8)  
Always 1943 (57.8) 385 (63.4) 250 (56.6)  889 (59.0) 419 (52.2)  
IDU=injection drug use 




Table 3.4. Model fit and selection criteria for latent classes of social support. 
Criteria Class 2 Class 3 Class 4 Class 5 
Parameters 29 44 59 74 
AIC 32687.306 31301.778 30665.369 30210.899 
BIC 1 32772.872 31431.602 30839.451 30429.238 
LMR(p) 2 <0.0001 <0.0001 0.1241 -- 
Entropy 0.945 0.921 0.920 0.900 
1 Sample size adjusted BIC 
2 Lo-Mendell Rubin adjusted likelihood ratio test for n versus n-1 classes 
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Table 3.5. Correlates of latent class membership for high and very high support compared to moderate support. 
 Bivariate Multivariable 
 High Very high High Very high 
Predictors OR (95 CI) OR (95 CI) AOR (95 CI) AOR (95 CI) 
Participant     
Female 1.12 (0.79, 1.59) 1.3 (0.92, 1.85)   
Age, years 1.01 (1.00, 1.03) 1.02 (1.00, 1.04)* 0.99 (0.96, 1.01) 0.99 (0.96, 1.01) 
Injected last 12 mos. 0.69 (0.49, 0.95)* 0.52 (0.37, 0.73)* 0.80 (0.52, 1.23) 0.85 (0.53, 1.36) 
Street drugs (not IDU) 0.63 (0.46, 0.88)* 0.43 (0.31, 0.60)* 0.82 (0.54, 1.24) 0.58 (0.37, 0.92)* 
Homelessness 0.55 (0.34, 0.89)* 0.31 (0.18, 0.53)* 0.86 (0.48, 1.51) 0.57 (0.28, 1.16) 
HIV-positive 0.94 (0.65, 1.34) 1.36 (0.96, 1.94)   
Depressive symptoms 0.65 (0.46, 0.92)* 0.36 (0.25, 0.53)* 0.93 (0.61, 1.43) 0.65 (0.39, 1.06) 
Network size=4-5 1.18 (0.85, 1.64) 0.63 (0.46, 0.88)* 0.97 (0.60, 1.56) 0.50 (0.29, 0.85)* 
 
Network member 
    
Female1 1.17 (1.02, 1.35)* 1.06 (0.92, 1.22) 1.08 (0.89, 1.30) 1.13 (0.91, 1.40) 
Age, mean years 1.02 (1.01, 1.04)* 1.03 (1.01, 1.05)* 1.03 (1.01, 1.05)* 1.03 (1.01, 1.05)* 
Injected drugs ever 1 0.93 (0.78, 1.11) 0.58 (0.46, 0.72)* 0.99 (0.79, 1.25) 0.75 (0.56, 1.00)* 
Street drugs ever 1 0.85 (0.75, 0.96)* 0.54 (0.47, 0.63)* 0.81 (0.69, 0.95)* 0.60 (0.49, 0.73)* 
Talk to daily1 1.39 (1.23, 1.58)* 1.43 (1.26, 1.63)* 1.33 (1.14, 1.56)* 1.54 (1.30, 1.83)* 
Do something enjoyable with 3.44 (2.45, 4.84)* 7.93 (5.36, 11.72)* 3.24 (2.20, 4.78)* 7.74 (4.87, 12.30)* 
Argue with always 1 0.92 (0.76, 1.12) 0.59 (0.46, 0.74)* 0.81 (0.64, 1.02) 0.59 (0.44, 0.78)* 
OR=odds ratio; AOR=adjusted odds ratio; CI=confidence interval; IDU=injection drug use 




Figure 3.1. Moderate support class with social support indicator response 
probabilities.  
 
Figure 3.2. High support class with social support indicator response probabilities.    
Talk Corner Pitch in Loan Stay Advice Health
None-A little 0.214 0.111 0.169 0.322 0.303 0.2 0.362
Sometimes-Freq. 0.56 0.53 0.626 0.47 0.396 0.586 0.484














Talk Corner Pitch in Loan Stay Advice Health
None-A little 0.058 0.021 0.035 0.087 0.093 0.039 0.113
Sometimes-Freq. 0.275 0.158 0.274 0.329 0.204 0.285 0.312

















Figure 3.3. Very high support class with social support indicator response 
probabilities.   
Talk Corner Pitch in Loan Stay Advice Health
None-A little 0.02 0.001 0.001 0.004 0.012 0.002 0.037
Sometimes-Freq. 0.044 0.007 0.005 0.01 0.007 0.008 0.054


























N (%) N (%) N (%) p value 
Sex 1604 (47.8) 1046 (49.5) 558 (44.8) 0.008 
Race 3228 (95.4) 2046 (96.1) 1182 (94.1) 0.006 
Age within 10 yrs. 1597 (47.2) 971 (45.6) 626 (49.8) 0.018 
HIV status 2359 (72.8) 1416 (69.7) 943 (78.1) <0.001 
Inject drugs, ever 505 (16.3) 268 (13.7) 237 (20.9) <0.001 
Inject drugs, 6 mos. 2256 (73.2) 1923 (98.7) 333 (29.4) <0.001 
Street drugs, ever 1887 (62.7) 1398 (73.6) 489 (44.1) <0.001 





Supplemental Table S.3.2. Multiplexity of alter roles. 








N (%) N (%) N (%) p value 
    <0.001 
0 371 (11.0) 191 9.0) 180 (14.3)  
1 227 6.7) 121 5.7) 106 (8.4)  
2 212 6.3) 113 5.3) 99 (7.9)  
3 256 7.6) 162 7.6) 94 (7.5)  
4 288 8.5) 173 8.1) 115 (9.1)  
5 365 (10.8) 215 (10.1) 150 (11.9)  
6 505 (14.9) 362 (17.0) 143 (11.4)  
7 1164 (34.4) 794 (37.3) 370 (29.4)  
IDU=injection drug use 




4. Frequency of emergency department visits among persons with a history of 
injection drug use with a focus on social network correlates 
 
4.1. Abstract 
Persons who inject drugs (PWID) have more frequent emergency department 
(ED) visits than the general population. Frequent ED visits can indicate inappropriate and 
inefficient use of healthcare resources. This study examines associations of ED visit 
frequency among a cohort of PWID with characteristics of their close social relationships 
including different types of social support from different types of social network 
members. 
Information was obtained from a sample of AIDS Linked to the IntraVenous 
Experience study participants at their six-month study visit from April 1, 2016 through 
June 30, 2017. Andersen’s behavioral model of healthcare use was used as a framework 
for the analysis. Multinomial logistic regression was used to determine odds ratios for the 
outcome of ED visit frequency (0, 1, ≥2 visits in the prior six months).  
Of 970 participants who completed a social network survey, the prevalence of 
having one ED visit in the prior six months was 15.7%, having two or more was 10.6% 
with 73.7% having no ED visits. Lack of transportation was the most prevalent barrier, 
increasing with increasing ED visit frequency from 31.4% of those with no ED visit to 
57.3% of those with two or more visits. In multivariable analysis, compared to no ED 
use, having one visit was significantly more common among participants with the 
predisposing characteristic of past year injection drug use (AOR: 1.53; 95% CI: 1.03, 
2.28) and less common for those with the enabling factor of informational support (AOR: 
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0.64; 95% CI: 0.41, 1.00). Compared to no ED use, having two or more visits was 
significantly more common among participants who had the predisposing characteristics 
of past year injection drug use (AOR: 1.69; 95% CI: 1.07, 2.67) and homelessness in the 
past six months (AOR: 3.32; 95% CI: 1.81, 6.07); the need factor of three or more non-
psychiatric/non-infectious comorbidities (AOR: 3.77; 95% CI: 2.25, 6.31) and the 
environmental factor of lacking transportation (AOR: 1.95; 95% CI: 1.22, 3.12). Two or 
more ED visits were significantly less common among participants with the enabling 
factor of having a partner (AOR: 0.56; 95% CI: 0.35, 0.90). 
Findings indicate that social networks of PWID represent a resource that may 
enable more optimal use of healthcare services and may be a valuable place to intervene 
to strengthen support systems that can potentially prevent vulnerabilities that lead to poor 
health and barriers to care, particularly for informational support from social network 
members and with partners. 
 
4.2. Background 
Appropriate ED use has been operationalized as the congruence between the 
emergency care setting and the level of medical care needed in addition to the frequency 
of visits (1). High frequency ED use indicates disparities in use of primary care that can 
lead to health conditions that could have been prevented in the ambulatory care setting 
(2). These ambulatory care-sensitive conditions include complications from diabetes, 
chronic obstructive pulmonary disease and heart failure and are used to lower 
government reimbursement for healthcare services (3). Injection drug use has been 
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implicated in suboptimal healthcare use, e.g., lower engagement in outpatient care and 
greater use of the ED or hospitalization (4, 5). Persons who inject drugs (PWID) have 
been estimated to have three times greater ED visits than the general population (6). 
Among persons who use substances, factors associated with greater likelihood of ED 
visits include co-occurring psychiatric comorbidity (4, 7-9), more frequent injection (10) 
and HIV-positive status (4, 10), more primary care utilization (10, 11), unstable housing 
(12, 13) and having more female social network members (14). A lower likelihood of ED 
visits has been found for persons having a regular healthcare provider, being on 
methadone treatment (4) or reporting good to excellent health (14). Among HIV-positive 
PWID, those with higher quality of engagement with their healthcare provider had lower 
odds of using the ED as a usual source of care (15). 
Andersen’s behavioral model of healthcare use provides a framework to organize 
individual, social and health system level factors that influence health behaviors and 
outcomes (16). It has been used to examine ED use among groups impacted by infectious 
disease (17), mental illness (18) and PWID (15). It organizes predictors of healthcare use 
into predisposing factors that indicate a predisposition to use healthcare existing prior to 
illness; enabling factors that facilitate use of healthcare; actual and perceived health 
needs; as well as environmental factors that include facilitators and barriers to care at the 
clinic and community level. The use of Andersen’s health behavior model to explain the 
association of social networks with ED use among PWID is limited. 
Support from social network members is also known to affect healthcare 
utilization behaviors (19). One’s social network is often characterized by the nature and 
composition of one’s relationships (i.e., relationship type and quality, types of social 
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resources available from their network contacts, etc.) (20). These resources can be 
categorized as the provision of informational (advice or guidance), emotional (comfort or 
encouragement) and instrumental support (tangible help). Some studies have found that 
for patients visiting EDs that serve urban and poor populations, having more network 
members providing social support or consulting a family member or friend before visiting 
the ED (8) reduces the likelihood of having two or more ED visits per year (8, 21). 
Conversely, frequent visitors to the ED report lower levels of social support overall (22). 
Having network members that use drugs has been shown to increase the likelihood of 
suboptimal ED use, defined as visits without a subsequent hospital admission (23). 
However, the contribution of social network factors to ED use among PWID is not well-
understood. For example, it is not known if ED use varies by both type of support and the 
source of support, i.e., which network member is being supportive in what way. 
The present study aims to identify factors associated with high frequency ED use 
among PWID and evaluate the role of individual and social network characteristics in 
patterns of ED utilization within the framework of Andersen’s behavioral model of 
healthcare use. Results can enhance our understanding about ED use among PWID and 
point to opportunities for interventions to reduce suboptimal healthcare utilization. 
4.3. Methods 
This study was an analysis of cross-sectional survey data from the AIDS Linked 
to the IntraVenous Experience (ALIVE) study. The ALIVE study is a longitudinal cohort 
which examines the epidemiology of injection drug use and associated health factors 
among adults 18 years of age or older with a history of injection drug use (24). ALIVE 
participants completed standardized questionnaires, Audio Computer-Assisted Self-
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Interview (ACASI), in-person interviews and provided bio-specimens for behavioral, 
socioeconomic and clinical parameters at 6-month visits. As described previously, a 
supplemental 59-question social network survey module was developed and used to 
gather information from participants about the attributes of their social network members, 
the nature of their relationships and the support they are available to provide. Data in this 
study are from 970 ALIVE participants who completed the supplemental social support 
survey in the from April 1, 2016, to June 30, 2017. 
 
4.3.1. Variables 
The healthcare use outcome of interest was frequency of ED visits in the prior six 
months. Frequent users defined as having four or more ED visits per year accounted for 
only 4%-8% of ED patients, but 21%-28% of ED visits (25). Therefore, for the six-month 
study period we categorized ED visit frequency as none, one or two or more to 
distinguish participants with very high use (≥2/6 months) from those with single visit, 
which is not as clearly high use given the short period of time.  
The primary exposure of interest, social support, was considered an enabling 
resource and was operationalized in three ways: 1) classes of social support intensity 
(moderate, high, very high) determined through multilevel latent class analysis using 
social support indicators from the level of ego-alter ties nested within participant social 
networks; 2) each of the seven social support indicators individually; and 3) the seven 
indicators aggregated by the constructs of informational, emotional and instrumental 
support. The Likert scale response categories for seven indicators of emotional, 
instrumental and informational social support were dichotomized to generate binary 
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variables indicating support was always or not always provided by the alter. We used this 
dichotomy because the proportion of ‘always’ responses was high, ranging from 62% to 
76%, while none of the other four options rose above 16% across all seven social support 
indicators. Variables for social support were defined as having one or more network 
member available to always provide the given support. 
The role of social support was further evaluated through stratifying each support 
construct by alter characteristics that may modify the association of social support with 
ED use: 1) partners; 2) female gender; and 3) injection drug use. Other social network 
enabling factors were network member demographics, quality and nature of relationship 
with participants, substance use behaviors and healthcare use. All alter characteristics 
were reported by the ego. 
Variables were examined within the framework of Andersen’s Behavioral Model. 
Need variables were self-reported health status, the number of comorbid health 
conditions other than infectious or behavioral health needs, HIV, hepatitis C and 
depressive symptoms. General health status was categorized as excellent to very good, 
good and fair to poor. Composite measures of comorbidities reduce the number of 
specific disease variables needed (26) and a large proportion of persons with ED visits 
have three or more comorbidities (27). Therefore, we created a binary variable was 
generated representing three or more comorbid chronic health conditions (diabetes 
mellitus, hypertension, heart disease, cardiovascular disease, stroke and renal disease). 
However, comorbidities of depressive symptoms, HIV and hepatitis C infection were 
examined separately given the strong associations with ED use shown for these 
conditions. Depressive symptoms were confirmed through administration of the Center 
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for Epidemiological Studies-Depression (CESD) with a cut off of 22 selected given that 
persons with history of opioid misuse score higher than the general population (28). HIV 
status was diagnosed through enzyme-linked immunosorbent assay and confirmed 
through Western blot. Chronic hepatitis C infection was defined as ever having had a 
positive anti-hepatitis C virus antibody test and detectable hepatitis C viral RNA 
measured through a study visit. Predisposing factors were general demographics as well 
as injection and non-injection drug use behaviors and treatment. Additional enabling 
factors beyond the social network factors described above were income, having a usual 
source of care and health insurance. Environmental factors were clinic wait times, 
transportation barriers and clarity of provider communication. 
 
4.3.2. Statistical analysis 
Descriptive statistics were used to compare participant demographics, substance 
use and social networks roles and characteristics using T tests for continuous and chi-
square tests for categorical measures. A prior study found that over 96% of persons living 
with HIV in this cohort were engaged in outpatient care in the previous six months. As 
outpatient care is highly correlated with ED use, we first compared participant 
characteristics by HIV-status to describe differences that may play a role in ED use. The 
tests of significance for comparisons of social network characteristics at the level of the 
participant-alter dyad were adjusted for correlations within individual networks by 
clustering on egos. Because of the potential for a high degree of correlation among 
variables within each domain of Andersen’s behavioral model, we tested tetrachoric 
correlations for substance use, comorbidity, environmental and social support binary 
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variables. Selection of highly correlated variables for modeling was based on the 
understanding their relationship, relative importance and role in healthcare behaviors. 
To explore the role of sources of support within ego networks on ED visit 
frequency, we used contingency tables comparing informational, emotional and 
instrumental support available within networks from combinations of alters that were 
female or male, partners or non-partners and those with a history of injection drug use or 
no injection drug use history. For example, ED visit frequency was compared across ego 
networks having: 1) a partner as the only source of support; 2) only from a non-partner; 
3) from both a partner and a non-partner; and 4) from neither a partner or non-partner.  
Multinomial logistic regression was used to determine associations with levels of 
ED visit frequency. Variables with significant associations (p≤0.05) were included in the 
final multivariable model. Participant age was included regardless of bivariate 
significance in the unadjusted analyses because of the well-established relationship of age 
with health status. We used contingency tables to further explore predisposing 
characteristics significantly associated with ED visit frequency by key enabling, need and 
environmental factors. Analyses were performed using Stata version 15.0 (StataCorp, 
College Station, TX). 
 
4.4. Results 
Table 4.1. stratifies characteristics of participants by their HIV serostatus. For 
predisposing factors, a greater proportion of participants living with HIV compared to 
those HIV-negative were black (91.8% vs. 83.4%; p<0.001) and were less likely to have 
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experienced homelessness in the prior six months (5.8% vs. 12.4%; p=0.002). They were 
less likely to use injection drugs (31.1% vs. 41.9%; p=0.002) and when they did report 
injection drug use they were less likely to report daily injection (10.6% vs. 14.5%; 
p=0.035). The only statistically significant difference among enabling resources was 
having a usual source of care, which was high for both but greater for persons living with 
HIV (97.6% vs. 86.1%; p<0.001). For need factors, persons living with HIV were 
significantly more likely to be co-infected with hepatitis C (62.3% vs. 53.1%; p=0.008). 
For environmental factors, persons living with HIV were more likely to report clear 
communication from providers (67.9% vs. 45.1%; p<0.001) and less likely to report that 
clinic wait times were too long (7.1% vs. 18.2%; p<0.001). In terms of health care use 
overall, the median number of ED visits was zero (range=0-7) with 715 (73.7%) having 
no ED visits, 152 (15.7%) having one and 103 (10.6%) having two or more ED visits in 
the prior six months, with no significant differences by HIV status. 
The proportion reporting barriers to care increased with increasing number of ED 
visits in the past six months (Table 4.2.). The most prevalent barriers were not having 
reliable transportation, (36.2%), followed by inability to afford care (21.1%), unstable 
housing (15.2%) and waiting too long at the clinic (14.8%) or too long to schedule 
appointments (14.6%). 
The proportion reporting three or more comorbidities increased as the number of 
ED visits increased (Supplemental table S.4.1.). The most common was hypertension 
(52.2%) followed by psychiatric comorbidities of depression (45.9%), anxiety/pain 
(25.7%) and bipolar (24.0%). The prevalence of lung disease (p<0.001), diabetes 
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p=0.011), heart problems (p<0.001), stroke (p<0.001) and renal disease (p=0.002) 
increased with increasing ED visit frequency as did all psychiatric conditions. 
 
4.4.1. Social network characteristics 
Most social network characteristics were similar across categories of ED visit 
frequency (Table 4.3.). Participants reported knowing their network members 32 years on 
average and daily interaction was common (87.6%). Ninety-two percent reported having 
at least one female alter and 38.7% had an alter with a history of injection drug use. 
Compared to those who reported no ED use, those who reported two or more visits to the 
ED were significantly less likely to have a partner (32.0% vs. 44.9%; p=0.013). Persons 
with no ED visits in the past six months were least likely to have an alter with at least one 
health condition (p=0.038). 
Most reported having at least one alter always available for emotional (92.1%) 
and instrumental (92.3%) support and there were no significant differences in the overall 
provision of support by frequency of ED use (Table 4.4.). However, compared to those 
with no ED visits, those with two or more were significantly less likely to report they had 
a partner who provided instrumental support (32% vs. 39.9%; p=0.029). There were no 
differences in ED use by persons who had instrumental or emotional support provided by 
female alters or those who use injection drugs.  
Most reported having at least one alter who was always available for 
informational support (84.6%). Compared to those who reported one ED visit, those with 
no or two or more visits were significantly more likely to report informational support 
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from any alter (86.0% and 86.3%, respectively, vs. 77.0%; p=0.017) or specifically from 
a partner (36.4% and 28.2%, respectively, vs. 24.3%; p=0.008). The most common 
source of all types of support was from female alters and the lowest from alters with a 
history of injection drug use. The pattern was similar for the seven individual social 
support indicators (Supplemental table S.4.2.). 
Comparing the composition of ego networks by combinations of a given alter trait 
(e.g. networks where a type of support is reported only from a partner, only from non-
partners, from both partners and non-partners or from neither partners or non-partners) 
revealed significant differences by ED use frequency for informational support provided 
by partners and female alters, but not emotional or instrumental support from any alter 
type (Supplemental Table S.4.3.). Participants with networks having a partner as the only 
source of informational support were more likely to have no ED visits (5.6%) compared 
to one (5.3%) and two or more visits (2.0%) and if the only source of informational 
support was from a non-partner they were less likely to have no ED visits (49.6%) 
compared to one (52.6%) and two or more visits (57.8). Participants networks having 
female alters as the only source of informational support were more likely to have one 
ED visit (30.3%) compared to no (26.3%) and two or more visits (20.4%) and if the only 
source of informational support in their network was from a male alter they were more 
likely to have no ED visits (9.6%) compared to one (7.9%) and two or more visits (6.8%).  
 
4.4.2. Associations with ED visit frequency 
Table 4.5. shows the results of multinomial logistic regression of the associations 
with ED visit frequency. Because there were no differences by HIV status for the key 
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domains of healthcare use and access and need that were hypothesized to differentiate 
HIV-positive from HIV-negative, it was evaluated as a potential confounder of the 
relationship between social support and ED visit frequency rather than through separate 
models stratified by HIV status. In the adjusted model compared to no ED use, having 
one visit was significantly more common among participants who had injected drugs in 
the past year (AOR: 1.53; 95% CI: 1.03, 2.28) and less common for those always 
informational support available from an alter (AOR: 0.64; 95% CI: 0.41, 1.00). Because 
the latent classes of intensity of social support were highly correlated with each of the 
three types of support, we chose to keep the specific construct for informational support 
in the adjusted model as it would be more explanatory of the role of a specific support 
type. Compared to no ED use, having two or more visits was significantly more common 
among participants who had injected drugs in the past year (AOR: 1.69; 95% CI: 1.07, 
2.67), been homeless in the past six months (AOR: 3.32; 95% CI: 1.81, 6.07), had three 
or more non-psychiatric/non-infectious comorbidities (AOR: 3.77; 95% CI: 2.25, 6.31) 
and lacked transportation (AOR: 1.95; 95% CI: 1.22, 3.12) ) and significantly less 
common among participants having a partner (AOR: 056; 95% CI: 0.35, 0.90).  
Comparing predisposing characteristics significant in the adjusted model by key 
enabling, need and environmental factors, we found that participants that were female 
were more likely to have a usual source of care, three or more comorbidities and report 
having to wait too long at the clinic (Supplemental Table S.5.4). Participants who 
injected drugs in the prior year were more likely to be homeless, have a partner, lack 
transportation and report long clinic wait times and less likely to have a usual source of 
care, have informational support or three or more comorbidities. Participants that 
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reported homelessness in the prior six months were more likely to report injection drug 
use, lack transportation and identify long clinic wait times as a barrier to care, and less 
likely to have a usual source of care, have informational and three or more comorbidities. 
 
4.5. Discussion 
In this sample of PWID, most were living below the national poverty level and 
had substantial barriers to care and chronic medical and psychiatric comorbidities, but 
also had high levels of enabling resources including health insurance, having a usual 
source of care and social support. About 27% of our study sample experienced at least 
one ED visit in the prior six months, lower than the 33% rate previously found among 
PWID in Baltimore (5) and lower than the national rate of about 35% annually for adults 
with Medicaid (29). About half of the participants had been to their primary care provider 
two or more times in the prior six months, which is consistent with national level data 
indicating that almost half of persons with ED visits attempted to contact an outpatient 
provider first (30). 
Social network attributes that were associated with less frequent ED use in our 
sample were having a partner and the availability of informational support. Fear of 
finding out about a new illness diagnosis can be a barrier to accessing care (31), while 
greater understanding of illness has been associated with reduced ED visit frequency 
(32). Additionally, persons who are actively using opioids and in pain may have a fear of 
withdrawal symptoms if their pain is not adequately treated by healthcare providers (33), 
which may factor into their healthcare seeking decisions.  
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Persons who use substances also experience barriers to care related to stigma and 
discrimination, difficulty communicating with medical providers and lack of knowledge 
about how and where to access care and consequently turn to their substance using peers 
for information (34). It may be that PWID in our study had gained enhanced 
understanding of their illness, help deciding if the acuity of an illness warranted a visit to 
the ED or support with medication adherence for their chronic health conditions by 
mobilizing the social resources within their networks for informational support, 
particularly from partners. These peers may provide an essential form of informational 
support that counterbalances the difficulty in communication they experience when 
interacting with healthcare providers and decision making about seeking care in general.  
Given perceptions around substance use and mental illness, service providers 
must be trained to recognize stigma and discrimination as a barrier to engaging in 
preventative outpatient care and engage in non-judging communication with persons with 
injection drug use that promote trusting relationships. Providers can screen patients for 
sources and types of social support to identify opportunities for encouraging interaction 
with supportive network members, such as having partners attend clinic visits or referring 
patients to social support groups if they lack support resources. 
We found that having a partner was protective of experiencing two or more ED 
visit and that persons receiving instrumental and informational support from their 
partners were less likely to have any ED visits. It has been shown that married couples 
experience better health than unmarried persons (35), and persons with a partner in our 
study, regardless of marital status and including partners, did have somewhat lower 
prevalence of multi-comorbidity. We found that a lower proportion of persons with a 
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partner reported having a transportation barrier than those without a partner, which may 
indicate that a partner can assist in meeting transportation needs. Given the positive 
influence of one partner’s adoption of health promoting behaviors on the other (36), 
partners represent an opportunity for influencing norms of engaging in outpatient care 
that may in turn avoid potentially preventable ED visits. Our findings indicate that 
intervening with partners and alters with a history of injection drug use may be one 
means for promoting diffusion of health behaviors that promote efficient use of 
healthcare resources.  
HIV seropositivity was not associated with ED visit frequency, despite a greater 
prevalence of hospitalization and hepatitis C co-infection among those living with HIV 
compared with HIV-negative participants. This may be related to the high level of 
engagement in outpatient care shown by the large proportion having a usual source of 
care, recent clinic visits, perceptions of clear communication with providers as well as 
lower levels of injection drug use. While participants living with HIV may have greater 
need for healthcare services, they have access to comprehensive essential services and 
community interventions supported through federally funded Ryan White HIV/AIDS 
Program HIV clinics (37) that are not available to HIV-negative PWID. 
Not having reliable transportation was an important barrier to accessing care and 
was found to be associated with greater ED visit frequency in the adjusted model. 
Nationally, over 50% of those having an ED visit in the past year reported not having 
transportation, and those without transportation had an 88% greater likelihood of having 
an ED visit (38). Despite high levels of engagement in outpatient care in our study, 
having a usual source of care may be necessary but may not sufficient to reduce ED visit 
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frequency when significant structural barriers to care exist. These barriers could 
potentially be addressed through locating clinics closer to populations in need and 
without effective means of public or personal transportation or providing clinic-based 
patient shuttle services and travel expense reimbursement. Presumably, having others in 
the social network to drive one to the clinic would address this barrier as well, although 
we did not find instrumental support in general to be associated with ED visit frequency. 
Potentially preventable ED visits and hospitalizations are defined in part by the 
presence of ambulatory care-sensitive conditions for which primary or other preventative 
care can reduce the need for more intensive services (39). Greater use of the ED has been 
related to a number ambulatory care-sensitive conditions, including heart disorders, 
diabetes, respiratory problems (26). A previous study of emergency medical service use 
in Baltimore found that chronic conditions, including diabetes, HIV and asthma were 
related to more frequent ED use (40). Our findings are similar, with three or more 
comorbidities associated with ED visits and differences found for prevalence of chronic 
lung disease, diabetes and heart disease. These are all health conditions that are most 
effectively managed by primary care and specialty providers in the outpatient setting, 
avoiding the need for emergency services. Additionally, linkage to harm reduction 
resources such as needle exchange programs have been shown to reduce ED visits (41), 
which may in part be a consequence of reduced skin infections related to injection drug 
use, one of the most common reasons for ED use among PWID (10, 42). 
As with previous studies (43, 44), we found high ED use to be associated with 
homelessness. While persons experiencing homelessness reported fewer comorbidities, 
they had a higher prevalence of injection drug use and transportation barriers and a lower 
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prevalence of available informational support or having a usual source of care, all of 
which were independently associated with ED use. Chronic illness along with substance 
use and homelessness represent a syndemic of interacting health problems (45). The 
prevalence of multi-comorbidity including mental illness and homelessness among this 
group of PWID confirms the need for comprehensive approaches to care and 




Limitations of the study include the lack of the diagnosis for ED visits to evaluate 
if use was preventable and whether an ED visit directly led to hospitalization. 
Consequently, while many health conditions can be treated in the primary care setting, 
others do require emergency services and we were not able to determine the 
appropriateness of ED use. However, we were able to look separately at persons who had 
more than 1 ED visit as a marker of potentially inappropriate use. We did not look at the 
primary mode of transportation or proximity of residence to healthcare services, which 
would be important to asses in the future given the level of perceived transportation 
barriers. With 96% of persons living with HIV in this cohort having had an outpatient 
care visit in prior six months, this cohort may not be representative of other populations 
with much lower levels engagement in care. Additionally, this analysis used cross-
sectional data from a single study visit and does not allow examination of the lag that 
may exist between an individual and social network exposures and ED use, limiting the 




Understanding factors associated with more frequent use of emergency services 
and implementing programs to reduce inappropriate use continues to be a priority of 
health systems and governments seeking to encourage preventive care, improve health 
outcomes and reduce health care spending. This study shows that certain modifiable 
social network and individual factors are associated with higher emergency care 
utilization. Social networks may thus be a valuable place to intervene and connect people 
with more effective and appropriate health care services, as well as to strengthen support 
systems that can prevent vulnerabilities that lead to poor health and barriers to care. Still, 
more research is needed to understand the process by which different types support from 
different types of network members may play a positive role in health and health-care 
seeking behaviors. Such research can inform the design of interventions to encourage 
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Table 4.1. Participant characteristics by HIV status. 
 Total HIV-negative HIV-positive  
 n=970 n=676 n=294  
Characteristic N (%) N (%) N (%) p-value 
Predisposing     
Age, median (IQR) 56 (50-60) 55 (49-60) 56 (51-60) 0.099 
Female 315 (32.5) 216 (32.0) 99 (33.7) 0.6 
Black, non-Hispanic 834 (86.0) 564 (83.4) 270 (91.8) <0.001 
Homelessness 1 101 (10.4) 84 (12.4) 17 (5.8) 0.002 
Injection drug use, any 2 374 (38.6) 283 (41.9) 91 (31.1) 0.002 
Inject heroin alone 1 176 (18.1) 141 (20.9) 35 (11.9) <0.001 
Inject cocaine alone 1 100 (10.3) 75 (11.1) 25 (8.5) 0.22 
Inject speedball 1 139 (14.3) 96 (14.2) 43 (14.6) 0.86 
Frequency of injection 1    0.035 
None 681 (70.4) 458 (67.9) 223 (76.1)  
<Daily 158 (16.3) 119 (17.6) 39 (13.3)  
Daily 129 (13.3) 98 (14.5) 31 (10.6)  
Crack cocaine 1 243 (25.1) 167 (24.7) 76 (25.9) 0.7 
Drug misuse, non-injection 1 382 (39.4) 271 (40.1) 111 (37.8) 0.49 
Opioid replacement therapy 1 478 (49.3) 343 (50.7) 135 (45.9) 0.17 
 
Enabling 
    
Income <5,000 1  626 (65.1) 430 (64.4) 196 (66.9) 0.45 
Health insurance 1 945 (97.6) 655 (97.2) 290 (98.6) 0.17 
Have usual source of care 868 (89.6) 581 (86.1) 287 (97.6) <0.001 
     
Need     
≥3 comorbidities (not HIV) 3 178 (18.4) 123 (18.2) 55 (18.7) 0.85 
Hepatitis C infection 4 535 (55.9) 353 (53.1) 182 (62.3) 0.008 
CESD>22 1,5 245 (25.3) 178 (26.3) 67 (22.8) 0.24 
Perceived health status    0.51 
Excellent-very good 328 (33.8) 222 (32.8) 106 (36.1)  
Good 327 (33.7) 235 (34.8) 92 (31.3)  
Fair-poor 315 (32.5) 219 (32.4) 96 (32.7)  
 
Environment 
    
Doctors explain things clearly 502 (52.0) 303 (45.1) 199 (67.9) <0.001 
No reliable transportation 351 (36.2) 246 (36.4) 105 (35.7) 0.83 




Table 4.1. continued. 
 Total HIV-negative HIV-positive  
 n=970 n=676 n=294  
Characteristic N (%) N (%) N (%) p-value 
Healthcare use     
≥1 hospital admission 1 140 (14.4) 82 (12.1) 58 (19.7) 0.002 
≥1 outpatient visit 1 764 (78.8) 499 (73.8) 265 (90.4) <0.001 
Emergency department visit 1    0.18 
None 715 (73.7) 509 (75.3) 206 (70.1)  
1 152 (15.7) 97 (14.3) 55 (18.7)  
≥2 103 (10.6) 70 (10.4) 33 (11.2)  
1 Over prior 6 months  
2 Over prior 12 months 
3 Diabetes mellitus, hypertension, heart disease, stroke, renal disease, respiratory disease, 
seizure disorder, dyslipidemia 
4 Detectable Hepatitis C RNA 
5 Center for Epidemiological Studies-Depression score greater than 22 
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Table 4.2. Barriers to healthcare by frequency of ED visits over the prior six months. 
 Total No ED visit 1 ED visit ≥2 ED visits  
 n=970 n=715 n=152 n=103  
Barrier to care 1,2 N (%) N (%) N (%) N (%) p-value 
No reliable transportation 351 (36.2) 224 (31.4) 68 (44.7) 59 (57.3) <0.001 
Can’t afford care 204 (21.1) 132 (18.6) 43 (28.3) 29 (28.2) 0.005 
Unstable housing 147 (15.2) 89 (12.4) 34 (22.4) 24 (23.3) <0.001 
Wait too long at clinic 144 (14.8) 90 (12.6) 27 (17.8) 27 (26.2) <0.001 
Wait too long for appointments 141 (14.6) 89 (12.4) 30 (19.9) 22 (21.4) 0.007 
Inconvenient appointments 120 (12.4) 72 (10.1) 24 (15.8) 24 (23.3) <0.001 
Don’t want to disclose drug use 93 (9.6) 56 (7.9) 24 (15.8) 13 (12.6) 0.006 
Active drug use makes it hard  90 (9.3) 54 (7.6) 17 (11.2) 19 (18.4) 0.001 
Don’t trust medical system 80 (8.2) 51 (7.1) 16 (10.5) 13 (12.6) 0.090 
Don't like doctors 74 (7.6) 45 (6.3) 19 (12.5) 10 (9.7) 0.023 
Provider does not care 73 (7.5) 42 (5.9) 17 (11.2) 14 (13.6) 0.004 
Don't understand instructions 45 (4.6) 26 (3.6) 11 (7.2) 8 (7.8) 0.045 
ED=emergency department 
1 Over the prior six months 




Table 4.3. Social network characteristics by frequency of ED visits in the prior six months. 
 Total No ED visits 1 ED visit ≥2 ED visits  
 n=970 n=715 n=152 n=103  
Characteristic N (%) N (%) N (%) N (%) p-value 
Network size, median (IQR) 3.5 (1.4) 3.5 (1.4) 3.5 (1.4) 3.6 (1.3) 0.79 
Years known, mean (SD) 32 (14) 33 (14) 32 (13) 31 (12) 0.50 
Age, median (IQR) 50 (42-57) 51 (42-57) 49 (41-55) 48(40-56) 0.079 
 
One or more network members 
     
Female  891 (92.7) 653 (92.4) 143 (94.7) 95 (92.2) 0.59 
Ever used injection drugs 351 (38.7) 267 (40.2) 51 (35.7) 33 (33.0) 0.28 
Ever used street drugs, not IDU 521 (57.6) 379 (57.1) 87 (61.7) 55 (55.6) 0.54 
Substance use self-help group 149 (18.0) 108 (17.8) 26 (19.3) 15 (17.2) 0.91 
HIV-positive  122 (12.8) 89 (12.7) 22 (14.6) 11 (10.8) 0.67 
Hepatitis C-positive 210 (22.4) 150 (21.7) 35 (24.0) 25 (25.0) 0.67 
Partner/spouse 409 (42.2) 321 (44.9) 55 (36.2) 33 (32.0) 0.013 
Relative  848 (87.4) 628 (87.8) 128 (84.2) 92 (89.3) 0.39 
Talk with daily  850 (87.6) 634 (88.7) 128 (84.2) 88 (85.4) 0.25 
Frequently-always argue 283 (29.2) 209 (29.3) 44 (28.9) 30 (29.1) 1.00 
≥1 health condition 629 (66.8) 450 (64.5) 109 (74.1) 70 (72.2) 0.038 
Regularly goes to outpatient clinic 1 607 (97.1) 434 (96.9) 105 (97.2) 68 (98.6) 0.74 
ED=emergency department 




Table 4.4. Availability of at least one source of three types of support by frequency of ED visits over the prior six months. 
 Total No ED visits 1 ED visit ≥2 ED visits  
 n=970 n=715 n=152 n=103  
Social support N (%) N (%) N (%) N (%) p-value 
Emotional support 1      
Any alter 892 (92.1) 660 (92.3) 137 (90.7) 95 (92.2) 0.81 
Partner 346 (35.7) 269 (37.6) 45 (29.6) 32 (31.1) 0.10 
Female 795 (82.5) 586 (82.7) 124 (81.6) 85 (82.5) 0.95 
Ever used injection drugs 279 (30.1) 215 (31.7) 37 (25.3) 27 (26.7) 0.23 
 
Instrumental support 1  
    
Any alter 895 (92.3) 665 (93.0) 135 (88.8) 95 (92.2) 0.21 
Partner 363 (37.4) 285 (39.9) 45 (29.6) 33 (32.0) 0.029 
Female 802 (83.2) 593 (83.5) 121 (80.1) 88 (85.4) 0.49 
Ever used injection drugs 279 (30.2) 213 (31.5) 39 (26.4) 27 (26.7) 0.34 
 
Informational support 1  
    
Any alter 820 (84.6) 615 (86.0) 117 (77.0) 88 (86.3) 0.017 
Partner 326 (33.6) 260 (36.4) 37 (24.3) 29 (28.2) 0.008 
Female 727 (75.3) 541 (76.2) 105 (69.1) 81 (78.6) 0.13 
Ever used injection drugs 262 (28.1) 202 (29.6) 33 (22.4) 27 (26.5) 0.20 
ED=emergency department 




Table 4.5. Associations with one and two or more ED visits compared to no ED visits over the prior six months. 
 Bivariate Multivariable 
 1 vs. no ED visits ≥ 2 vs. no ED visits 1 vs. no ED visits ≥ 2 vs. no ED visits 
Factor OR (CI) OR (CI) AOR (CI) AOR (CI) 
Predisposing     
Age, years 1.00 (0.98, 1.02) 0.99 (0.97, 1.01) 1.00 (0.98, 1.03) 1.00 (0.97, 1.02) 
Female 1.08 (0.74, 1.58) 1.99 (1.31, 3.02)* 1.11 (0.75, 1.65) 1.69 (1.07, 2.67)* 
Income < $5, 000 1 1.20 (0.82, 1.75) 1.03 (0.67, 1.58)   
Homelessness 1 1.78 (1.04, 3.07)* 3.77 (2.23, 6.39)* 1.52 (0.85, 2.73) 3.32 (1.81, 6.07)* 
Injection drug use 2 1.60 (1.12, 2.28)* 1.96 (1.29, 2.97)* 1.53 (1.03, 2.28)* 1.65 (1.00, 2.70)* 
     
Enabling     
Network size>3 0.94 (0.66, 1.33) 1.12 (0.74, 1.69)   
Alter age, mean years 0.99 (0.97, 1.00) 0.98 (0.96, 1.00)   
Partner/spouse 3 0.70 (0.48, 1.00)* 0.58 (0.37, 0.90)* 0.73 (0.50, 1.06) 0.56 (0.35, 0.90)* 
Female alters, number 1.01 (0.87, 1.18) 0.97 (0.81, 1.16)   
Alter ever used injection drugs 3 0.82 (0.57,1.20) 0.73 (0.47,1.14)   
 
Social support constructs 1, 4 
    
Emotional  0.82 (0.44, 1.51) 0.99 (0.46, 2.14)   
Instrumental  0.60 (0.33, 1.07) 0.89 (0.41, 1.94)   
Informational  0.54 (0.35, 0.84)* 1.02 (0.56, 1.87) 0.64 (0.41, 1.00)* 1.50 (0.79, 2.87) 
All constructs 
 
1.11 (0.55, 2.24) 1.27 (0.53, 3.03)   
Intensity of support     
Moderate 1 1   
High 0.77 (0.50, 1.18) 0.85 (0.50, 1.45)   
Very high 0.58 (0.37, 0.92)* 0.94 (0.56, 1.59)   




Table 4.5. continued. 
 Bivariate Multivariable   
 1 vs. no ED visits ≥ 2 vs. no ED visits 1 vs. no ED visits ≥ 2 vs. no ED visits 
Factor OR (CI) OR (CI) AOR (CI) AOR (CI) 
Need     
HIV-positive 1.40 (0.97, 2.02) 1.16 (0.75, 1.82)   
Hepatitis C infection 1.12 (0.79, 1.60) 1.28 (0.84, 1.95)   
≥3 comorbidities (not including HIV) 5 1.58 (1.02, 2.44)* 3.32 (2.12, 5.21)* 1.52 (0.96, 2.43) 3.77 (2.25, 6.31)* 
Depressive symptoms 6 1.25 (0.84, 1.86) 2.24 (1.45, 3.45)* 0.85 (0.55, 1.33) 1.37 (0.83, 2.26) 
Perceived general health status     
Excellent-very good 1 1 1 1 
Good 1.08 (0.69, 1.70) 1.23 (0.71, 2.13) 0.93 (0.59, 1.49) 0.85 (0.47, 1.53) 
Fair-poor 1.88 (1.23, 2.88)* 2.24 (1.34, 3.74)* 1.51 (0.96, 2.39) 1.30 (0.73, 2.30) 
     
Environment     
Lack transportation 1.77 (1.24, 2.53)* 2.93 (1.92, 4.47)* 1.41 (0.95, 2.07) 1.95 (1.22, 3.12)* 
Wait too long at clinic 1.50 (0.94, 2.40) 2.47 (1.51, 4.03)* 1.09 (0.65, 1.82) 1.22 (0.69, 2.16) 
≥1 outpatient visit 1.44 (0.91, 2.28) 1.73 (0.97, 3.07)   
ED=emergency department; OR=odds ratio; AOR=adjusted odds ratio; CI=confidence interval 
* p≤ 0.05; OR=odds ratio 
1 Over the prior six months 
2 Over prior 12 months 
3 ≥1 network members with given characteristic 
4  Network member always provides at least one indicator for each construct 
5 Diabetes mellitus, hypertension, heart disease, stroke, renal disease, respiratory disease, seizure disorder, dyslipidemia  




Table S.4.1. Self-reported ever having had chronic comorbidities by frequency of ED visits over the prior six months. 
 Total No ED visits 1 ED visit ≥2 ED visits  
 n=970 n=715 n=152 n=103  
Comorbidity N (%) N (%) N (%) N (%) p-value 
Number comorbidities 1     <0.001 
0 311 (32.1) 248 (34.7) 42 (27.6) 21 (20.4)  
1 286 (29.5) 225 (31.5) 43 (28.3) 18 (17.5)  
2 195 (20.1) 135 (18.9) 34 (22.4) 26 (25.2)  
≥3 178 (18.4) 107 (15.0) 33 (21.7) 38 (36.9)  
Hypertension 506 (52.2) 359 (50.2) 83 (54.6) 64 (62.1) 0.062 
Chronic lung disease 2 209 (21.5) 128 (17.9) 38 (25.0) 43 (41.7) <0.001 
High cholesterol 200 (20.6) 139 (19.4) 35 (23.0) 26 (25.2) 0.29 
Diabetes (high blood sugar) 155 (16.0) 101 (14.1) 28 (18.4) 26 (25.2) 0.011 
Heart problem 3 82 (8.5) 50 (7.0) 13 (8.6) 19 (18.4) <0.001 
Seizures 4 56 (5.8) 39 (5.5) 6 (3.9) 11 (10.7) 0.060 
Stroke  56 (5.8) 33 (4.6) 9 (5.9) 14 (13.6) 0.001 
Renal disease or failure 42 (4.3) 23 (3.2) 8 (5.3) 11 (10.7) 0.002 
Psychiatric comorbidities      
Depression 445 (45.9) 298 (41.7) 87 (57.2) 60 (58.3) <0.001 
Anxiety/panic 249 (25.7) 167 (23.4) 44 (28.9) 38 (36.9) 0.008 
Bipolar (manic depression) 233 (24.0) 148 (20.7) 50 (32.9) 35 (34.0) <0.001 
Schizophrenia 5 45 (4.6) 29 (4.1) 6 (3.9) 10 (9.7) 0.035 
ED=emergency department 
1 Non-psychiatric and non-communicable 
2 Asthma, Chronic obstructive pulmonary disease, emphysema, not pneumonia 
3 Angina, heart attack, congestive heart failure 
4 Epilepsy, convulsions 
5 Schizophrenia / Schizoaffective disorder  
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Table S.4.2. Social support available from types of alters by frequency of ED visits over the prior six months. 
 Total No ED visits 1 ED visit ≥2 ED visits  
 n=970 n=715 n=152 n=103  
Social support N (%) N (%) N (%) N (%) p-value 
Intensity of support     0.21 
Moderate 247 (25.6) 172 (24.2) 48 (32.0) 27 (26.2)  
High 363 (37.7) 269 (37.8) 58 (38.7) 36 (35.0)  
Very High 354 (36.7) 270 (38.0) 44 (29.3) 40 (38.8)  
      
Emotional support 1      
Could talk to if down      
Any alter 780 (80.5) 574 (80.3) 124 (82.1) 82 (79.6) 0.85 
Partner 304 (31.3) 239 (33.4) 36 (23.7) 29 (28.2) 0.048 
Female 685 (71.1) 502 (70.8) 110 (72.4) 73 (70.9) 0.93 
Ever used injection drugs 234 (25.0) 180 (26.2) 33 (22.0) 21 (20.8) 0.33 
Would say is in your corner      
Any alter 859 (89.0) 641 (90.3) 127 (83.6) 91 (88.3) 0.054 
Partner 324 (33.4) 254 (35.5) 41 (27.0) 29 (28.2) 0.062 
Female 759 (78.9) 563 (79.6) 115 (75.7) 81 (78.6) 0.55 
Ever used injection drugs 258 (27.7) 200 (29.3) 33 (22.4) 25 (24.8) 0.19 
      
Instrumental support 1      
Would pitch in to help do things      
Any alter 800 (82.7) 600 (84.0) 117 (77.0) 83 (82.2) 0.11 
Partner 306 (31.5) 243 (34.0) 35 (23.0) 28 (27.2) 0.018 
Female 705 (73.2) 527 (74.2) 103 (68.2) 75 (73.5) 0.32 
Ever used injection drugs 226 (24.1) 176 (25.7) 32 (21.5) 18 (17.6) 0.15 
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Table S.4.2 continued.      
 Total No ED visits 1 ED visit ≥2 ED visits  
 n=970 n=715 n=152 n=103  
Social support N (%) N (%) N (%) N (%) p-value 
Would loan over $25      
Any alter 767 (79.2) 577 (80.8) 111 (73.5) 79 (76.7) 0.11 
Partner 308 (31.8) 246 (34.4) 37 (24.3) 25 (24.3) 0.012 
Female 660 (68.5) 492 (69.3) 99 (66.0) 69 (67.0) 0.69 
Ever used injection drugs 211 (22.4) 164 (23.9) 28 (18.4) 19 (18.6) 0.22 
Would let stay if needed a place      
Any alter 827 (85.3) 617 (86.3) 127 (83.6) 83 (80.6) 0.25 
Partner 334 (34.4) 263 (36.8) 42 (27.6) 29 (28.2) 0.036 
Female 732 (75.9) 544 (76.6) 113 (74.3) 75 (72.8) 0.63 
Ever used injection drugs  238 (25.4) 180 (26.2) 33 (22.3) 25 (24.8) 0.61 
      
Informational support 1      
Someone to give situation advice      
Any alter 785 (80.9) 592 (82.8) 112 (73.7) 81 (78.6) 0.028 
Partner 304 (31.3) 245 (34.3) 34 (22.4) 25 (24.3) 0.004 
Female 686 (71.1) 512 (72.1) 100 (65.8) 74 (71.8) 0.29 
Ever used injection drugs 243 (26.0) 189 (27.6) 33 (22.3) 21 (20.6) 0.17 
Does help understand health      
Any alter 702 (72.9) 521 (73.3) 106 (70.7) 75 (73.5) 0.80 
Partner 278 (28.7) 217 (30.3) 34 (22.4) 27 (26.2) 0.12 
Female 621 (64.4) 457 (64.3) 95 (62.9) 69 (67.0) 0.80 




1 Network member always provides support for indicator  
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Table S.4.3. Social support available from at least one type of alter by frequency of ED visits over the prior six months. 
 Total No ED visits 1 ED visit ≥2 ED visits  
 n=970 n=715 n=152 n=103  
Social support construct 1 N (%) N (%) N (%) N (%) p-value 
Emotional      
Partner Non-partner     0.44 
Yes Yes 305 (31.5) 237 (33.1) 38 (25.2) 30 (29.1)  
Yes No 41 (4.2) 32 (4.5) 7 (4.6) 2 (1.9)  
No Yes 546 (56.3) 391 (54.7) 92 (60.9) 63 (61.2)  
No No 77 (7.9) 55 (7.7) 14 (9.3) 8 (7.8)  
Female Male     0.75 
Yes Yes 549 (57.0) 407 (57.4) 79 (52.0) 63 (61.2)  
Yes No 246 (25.5) 179 (25.2) 45 (29.6) 22 (21.4)  
No Yes 90 (9.3) 67 (9.4) 13 (8.6) 10 (9.7)  
No No 79 (8.2) 56 (7.9) 15 (9.9) 8 (7.8)  
Ever inject Never inject     0.44 
Yes Yes 224 (24.2) 177 (26.1) 27 (18.5) 20 (19.8)  
Yes No 55 (5.9) 38 (5.6) 10 (6.8) 7 (6.9)  
No Yes 552 (59.6) 396 (58.3) 91 (62.3) 65 (64.4)  




Table S.4.3. continued. 
 Total No ED visits 1 ED visit ≥2 ED visits  
 n=970 n=715 n=152 n=103  
Social support construct 1 N (%) N (%) N (%) N (%) p-value 
Instrumental      
Partner Non-partner     0.14 
Yes Yes 317 (32.7) 251 (35.2) 37 (24.3) 29 (28.2)  
Yes No 46 (4.7) 34 (4.8) 8 (5.3) 4 (3.9)  
No Yes 531 (54.8) 379 (53.1) 90 (59.2) 62 (60.2)  
No No 75 (7.7) 50 (7.0) 17 (11.2) 8 (7.8)  
Female Male     0.47 
Yes Yes 547 (56.7) 404 (56.9) 78 (51.7) 65 (63.1)  
Yes No 255 (26.5) 189 (26.6) 43 (28.5) 23 (22.3)  
No Yes 86 (8.9) 66 (9.3) 13 (8.6) 7 (6.8)  
No No 76 (7.9) 51 (7.2) 17 (11.3) 8 (7.8)  
Ever inject Never inject     0.12 
Yes Yes 226 (24.4) 178 (26.3) 28 (18.9) 20 (19.8)  
Yes No 53 (5.7) 35 (5.2) 11 (7.4) 7 (6.9)  
No Yes 556 (60.1) 404 (59.8) 87 (58.8) 65 (64.4)  




Table S.4.3. continued. 
 Total No ED visits 1 ED visit ≥2 ED visits  
 n=970 n=715 n=152 n=103  
Social support construct 1 N (%) N (%) N (%) N (%) p-value 
Informational      
Partner Non-partner     0.011 
Yes Yes 276 (28.5) 220 (30.8) 29 (19.1) 27 (26.5)  
Yes No 50 (5.2) 40 (5.6) 8 (5.3) 2 (2.0)  
No Yes 493 (50.9) 354 (49.6) 80 (52.6) 59 (57.8)  
No No 149 (15.4) 100 (14.0) 35 (23.0) 14 (13.7)  
Female Male     0.023 
Yes Yes 473 (49.0) 354 (49.9) 59 (38.8) 60 (58.3)  
Yes No 254 (26.3) 187 (26.3) 46 (30.3) 21 (20.4)  
No Yes 87 (9.0) 68 (9.6) 12 (7.9) 7 (6.8)  
No No 151 (15.6) 101 (14.2) 35 (23.0) 15 (14.6)  
Ever inject Never inject     0.079 
Yes Yes 205 (22.0) 160 (23.4) 24 (16.3) 21 (20.6)  
Yes No 57 (6.1) 42 (6.1) 9 (6.1) 6 (5.9)  
No Yes 506 (54.3) 372 (54.5) 75 (51.0) 59 (57.8)  
No No 164 (17.6) 109 (16.0) 39 (26.5) 16 (15.7)  
ED=emergency department 
1 ≥1 alters always available to provide support for each support construct derived by aggregating seven individual indicators into 




Table S.4.4. Associations of sources of support with predisposing, enabling, need and environmental factors. 
 Female 1 Injection drug use 1 








n=595 Yes n=374  
Factor N (%) N (%) N (%) p-value N (%) N (%) N (%) p-value 
Predisposing         
Female -- -- -- -- 315 (32.5) 201 (33.8) 114 (30.5) 0.29 
Homelessness 1 101 (10.4) 66 (10.1) 35 (11.1) 0.62 101 (10.4) 30 (5.0) 71 (19.0) <0.001 
Injection drug use 2 374 (38.6) 260 (39.8) 114 (36.2) 0.29 -- -- -- -- 
 
Enabling         
Usual source of care 868 (89.6) 577 (88.2) 291 (92.4) 0.047 867 (89.6) 545 (91.6) 322 (86.3) 0.009 
Partner/spouse  409 (42.2) 276 (42.1) 133 (42.2) 0.98 409 (42.2) 232 (39.0) 177 (47.3) 0.011 
Informational support 1 820 (84.6) 546 (83.4) 274 (87.3) 0.12 819 (84.6) 517 (87.0) 302 (80.7) 0.008 
 
Need         
≥3 comorbidities  3 178 (18.4) 103 (15.7) 75 (23.8) 0.002 178 (18.4) 127 (21.3) 51 (13.6) 0.003 
 
Environmental         
Lack transportation 351 (36.2) 227 (34.7) 124 (39.4) 0.16 350 (36.2) 164 (27.6) 186 (49.9) <0.001 
Wait too long at clinic 144 (14.8) 75 (11.5) 69 (21.9) <0.001 144 (14.9) 57 (9.6) 87 (23.3) <0.001 
1 Over prior 6 months  
2 Over prior 12 months 
3 Diabetes mellitus, hypertension, heart disease, stroke, renal disease, respiratory disease, seizure disorder, dyslipidemia
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Table S.4.4. continued. 
 Homeless 1 





Factor N (%) N (%) N (%) p-value 
Predisposing     
Female 315 (32.5) 280 (32.2) 35 (34.7) 0.62 
Homelessness 1 -- -- -- -- 
Injection drug use 2 374 (38.6) 303 (34.9) 71 (70.3) <0.001 
 
Enabling 
    
Usual source of care 868 (89.6) 789 (90.8) 79 (79.0) <0.001 
Partner/spouse  409 (42.2) 370 (42.6) 39 (38.6) 0.45 
Informational support 1 820 (84.6) 744 (85.7) 76 (75.2) 0.006 
 
Need 
    
≥3 comorbidities  3 178 (18.4) 168 (19.3) 10 (9.9) 0.020 
 
Environmental 
    
Lack transportation 351 (36.2) 290 (33.4) 61 (61.0) <0.001 
Wait too long at clinic 144 (14.8) 75 (11.5) 69 (21.9) <0.001 
1 Over prior 6 months  
2 Over prior 12 months 
3 Diabetes mellitus, hypertension, heart disease, stroke, renal disease, respiratory disease, 




5. The role of social support in promoting viral suppression among persons with a 
history of injection drug use and living with HIV 
 
5.1. Abstract 
HIV viral suppression is essential to prevent disease progression and population 
level HIV transmission. Persons who inject drugs (PWID) are often less likely to achieve 
HIV viral suppression than those who do not inject drugs. Because injection drug use is a 
stigmatized behavior and PWID often have many health needs, the social networks of 
PWID may have an important influence on health behaviors and outcomes. The aim of 
this study is to understand the social network factors associated with suboptimal viral 
suppression among PWID.  
Information was obtained from a sample of AIDS Linked to the IntraVenous 
Experience study participants at their six-month study visit from April 1, 2016 through 
June 30, 2017. Networks were described using egocentric network analysis and odds 
ratios for the outcome of viral suppression <50 HIV RNA were determined with logistic 
regression. 
Of 293 participants with confirmed HIV seropositive status and a documented 
HIV RNA viral load who completed the supplemental social support survey, 49.5% were 
virally suppressed at their last visit. Engagement in care indicated by a visit with an HIV 
provider (96.4%) and antiretroviral use (84.6%) in the last six months were high and 
similar regardless of viral suppression status. Compared to those with a detectable viral 
load, a greater proportion of those with viral suppression were female (40.7% vs. 26.4%; 
p=0.009) and reported that their wishes were considered by their HIV care provider 
 
 110 
(69.0% vs. 66.7%; p=0.013). Compared to those with a detectable viral load, a greater 
proportion of persons who were virally suppressed had at least one HIV-positive alter 
(32.2% vs. 19.4%; p=0.014), a partner (42.8% vs. 30.4%; p=0.028) and an HIV-positive 
partner (17.2% vs. 4.1%; p<0.001) within their social network. In multivariable analysis, 
there were greater odds of viral suppression with each increasing year of age (AOR: 1.04; 
95% CI: 1.01, 1.08), female sex (AOR: 2.44; 95% CI: 1.42, 4.23), reporting that their 
wishes were considered by their HIV provider (AOR: 1.86; 95% CI: 1.10, 3.14) and 
having at least one HIV-positive alter (AOR: 2.02; 95% CI: 1.12, 3.64).  
Findings indicate that having network members who are HIV-positive may be 
supportive of viral suppression, which may be related to the positive influence of 
disclosure of HIV status to a peer and receiving support from persons who share the 
experience of living with HIV. In addition, healthcare providers promoting shared 
decision making with their patients living with HIV and a history of injection drug use 
may be help PWID acheive viral suppression. 
 
5.2. Background 
In the United States, of the people living with HIV (PLWH) who received any 
HIV care, 80% achieved viral suppression at their last viral load test (1). Among persons 
who inject drugs (PWID) the proportion virally suppressed is lower, 74.9% to 77.6% 
among female and male PWID, respectively. Historically, PWID have experienced lower 
rates of engagement in care, prescription of antiretroviral treatment (ART) and viral 
suppression (2-4) compared to all other transmission categories, although these 
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disparities have diminished overtime in some clinic cohorts (5, 6). With the importance 
of viral suppression to individual health outcomes and population level HIV transmission, 
there is a need to understand the factors associated with suboptimal viral suppression 
among PWID in the modern ART era.  
People living with HIV require access to care for lifelong treatment of HIV 
infection with ART. The goal of ART is to suppress HIV RNA viral load to below 
detectable limits and maintain immune function as indicated by CD4+ T cell over time, 
which requires consistent ART medication adherence (7). Among PWID, about 85% 
achieved viral suppression if they had 95% or greater adherence to medication (8). A 
number of structural and individual level factors have been related to retention in care 
and medication adherence. Barriers to care include lack of transportation and unstable 
housing (9). Antiretroviral medication non-adherence has been associated with drug use 
(8, 10), poor treatment by healthcare providers and stigma among healthcare providers 
towards PWID (10). However, differences in viral suppression by injection drug use are 
not always observed when measured longitudinally with continued retention in care and 
ART adherence (11). While these factors have a role in achieving HIV viral suppression, 
they do not fully explain the variability in viral suppression among PWID. 
In addition to the barriers to care and treatment PWID living with HIV can 
experience, they also have considerable need for healthcare services given the high 
prevalence of comorbidities associated with aging among PLWH (12) and high rates of 
infectious diseases among PWID (13-15). Thus, their social networks may have an 
important influence on health behaviors and outcomes. Social networks can influence 
health-related behaviors through social norms, injunctive (what others 
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approve/disapprove) and descriptive (what others appear to do) and social capital--the 
quantity and quality of tangible and intangible resources available within one’s social 
network (16). Most work with social networks factors and PWID have focused on HIV 
risk behaviors and their relationship with norms of safe sex (17) and drug use (18), but 
their role in healthcare use and treatment behaviors is not well-understood in this 
population. 
Social networks are often defined as an individuals’ social ties with their network 
members, referred to as their alters, and the resources available through these 
relationships (19). Among persons living with HIV, social support (20) and disclosure of 
HIV-positive status to more social network members (21) has been associated with 
retention in care. Among PWID living with HIV, there is some evidence to suggest that 
retention in care is related to emotional support (22, 23). However, knowledge of the 
types and sources of social support that best promote health outcomes like viral 
suppression is limited. 
The purpose of this study is to examine associations with viral suppression among 
PWID living with HIV with a focus on the types and sources of social support that may 
address challenges to accessing care and ART adherence. Study findings can inform 
efforts to support PWID in achieving viral suppression and downstream public health 





This study was an analysis of cross-sectional survey data from the AIDS Linked 
to the IntraVenous Experience (ALIVE) study. The ALIVE study is a longitudinal cohort 
which examines the epidemiology of injection drug use and associated health factors 
among adults 18 years of age or older with a history of injection drug use (24). ALIVE 
participants completed standardized questionnaires, Audio Computer-Assisted Self-
Interview (ACASI), in-person interviews and provided bio-specimens for behavioral, 
socioeconomic and clinical parameters at 6-month visits. As described previously, a 
supplemental 59-question social network survey module was developed and used to 
gather information from participants about the attributes of their social network members, 
the nature of their relationships and the support they are available to provide. Data in this 
study are from 970 ALIVE participants who completed the supplemental social support 
survey in the from April 1, 2016, to June 30, 2017. 
 
5.3.1. Variables 
The outcome of interest was HIV RNA viral suppression. HIV status was 
diagnosed through enzyme-linked immunosorbent assay and confirmed through Western 
blot. The limit of detection on all viral load tests was 50 HIV RNA copies/ml of blood. 
Participants experiencing ‘blips’ in detectable viral load, defined as an isolated detectable 
HIV RNA below 200 copies preceded by viral suppression and returning to below 
detectable limits at the next laboratory measure (25) were considered virally suppressed. 
The upper limit of a blip was set at 200 copies as HIV RNA above 200 may indicate 
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virologic failure. Various viral load cutoffs were tested to evaluate sensitivity of model 
outcomes to different definitions of viral suppression. 
The primary exposure of interest, social support, was considered an enabling 
resource and was operationalized in three ways: 1) classes of social support intensity 
(moderate, high, very high) determined through multilevel latent class analysis using 
social support indicators from the level of ego-alter ties nested within participant social 
networks; 2) each of the seven social support indicators individually; and 3) the seven 
indicators aggregated by the constructs of informational, emotional and instrumental 
support. The Likert scale response categories for seven indicators of emotional, 
instrumental and informational social support were dichotomized to generate binary 
variables indicating support was always or not always provided by the alter. We used this 
dichotomy because the proportion of ‘always’ responses was high, ranging from 62% to 
76%, while none of the other four options rose above 16% across all seven social support 
indicators. Variables for social support were defined as having one or more network 
member available to always provide the given support. Other social network enabling 
factors were network member demographics, quality and nature of relationship with 
participants, substance use behaviors and healthcare use. All alter characteristics are 
reported by the ego. 
Variables for health status were defined through self-report of ever having 
medical comorbidities including diabetes mellitus, hypertension, heart disease, 
cardiovascular disease, stroke and renal disease. Depressive symptoms was confirmed 
through administration of the Center for Epidemiological Studies-Depression (CESD) 
with cut off of 22 selected given that persons with history of opioid misuse score higher 
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than the general population (26). Chronic hepatitis C infection was defined as ever having 
had a positive anti-hepatitis C virus antibody test and detectable hepatitis C viral RNA 
measured at a study visit. Antiretroviral treatment regimens were identified based on 
participant self-report of medications taken in the previous six months with assistance by 
visual depictions of medications. and the reason reported for stopping any ART 
medication. The reasons reported for stopping ART in the previous six months were 
categorized at the level of the patient (non-adherence; side effects; pill burden) and 
provider initiated (drug interactions; virologic failure-drug resistance; immunologic 
failure/no recovery in low CD4 T cell counts; viral suppression). 
 
5.3.2. Statistical analysis 
Descriptive statistics were used to compare participant demographics, substance 
use and social network characteristics and roles by viral load suppression using t-tests for 
continuous and chi-square tests for categorical measures. The association of social 
support indicators and constructs with viral suppression was first examined for 
differences in the distribution of support stratified by alters with key characteristics 
across personal networks: 1) HIV-positive alters; 2) alters that are partners; 3) alters who 
had ever injected drugs; and 4) female alters. Because these attributes can overlap, we 
further evaluated the joint distribution of social support available from alters with 
characteristics found to be individually statistically significant. To explore the role of 
sources of support within ego networks on viral suppression, we used contingency tables 
comparing informational, emotional and instrumental support available within networks 
from combinations of alters that were female or male, partners or non-partners and those 
 
 116 
with a history of injection drug use or no injection drug use history. For example, viral 
suppression was compared across ego networks having: 1) a partner as the only source of 
support; 2) only from a non-partner; 3) from both a partner and a non-partner; and 4) 
from neither a partner or non-partner. The variance inflation factor was calculated to 
identify multicollinear independent variables.  
Logistic regression was used to determine associations with viral suppression. 
Non-collinear variables with statistically significant associations (p≤0.05) were included 
in the final multivariable model. Participant age and gender were included regardless of 
significance because of their well-established relationship with health behaviors and 




There were 293 ALIVE participants with confirmed HIV seropositive status and a 
documented HIV viral load who completed the supplemental social support survey. 
Overall, 145/293 (49.5%) were virally suppressed (Table 5.1.). Among persons that were 
virally suppressed at the visit of interest for this analysis, 83.0% and 87.1% were also 
suppressed at the previous and next 6-month study visits, respectively. A smaller 
proportion of persons with viral suppression had at least one hospital admission in the 
prior six months (14.5% vs. 24.3%; p=0.033). Engagement in care indicated by a visit 
with an HIV provider (96.4%) and ART use (85.6%) in the last six months were high 
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regardless of viral suppression status. There were no statistically significant differences in 
viral suppression by substance use, health status or health-related knowledge.  
The most prevalent barrier to accessing health care was not having reliable 
transportation (35.8%), followed by inability to afford care (18.5%), although there were 
no statistically significant differences by viral suppression stratus for any barriers (Table 
5.2.). The most common reasons for stopping any ART medication were having too many 
pills (30.9%), with no difference by viral suppression, while 27% of persons reporting 
being on ART in the previous six months were on a single pill regimen. Of those 
reporting ART use, about half (53.4%) were taking one of the recommended initial 
regimens (Supplemental Table S.5.1.). 
About 19% reported more than three comorbidities (Supplemental Table S.5.2.). 
The most common were hypertension (49.1%) and depression (49.5%), followed by 
bipolar (25.6%) and lung disease (23.9%), with no differences for any comorbidities by 
viral suppression status. 
There were differences in viral suppression observed for a number of social 
network factors (Table 5.3.). Persons who were virally suppressed had slightly larger 
median social network size (4 vs. 3; p=0.010) and a greater proportion had at least one 
HIV-positive alter (32.2% vs. 19.4%; p=0.014), partner (42.8% vs. 30.4%; p=0.028) and 
HIV-positive partner (17.2% vs. 4.1%; p<0.001). Person who were virally suppressed 
were more likely to have at least one HIV-positive alter available for emotional (28.5% 
vs. 16.4%; p=0.014), instrumental (27.8% vs. 16.4%; p=0.20) and informational support 
(27.1% vs. 15.0%; p=0.011) (Table 5.4.). Similarly, a greater proportion of the virally 
suppressed had a partner available for emotional (40.0% vs. 26.4%; p=0.013), 
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instrumental (40.7% vs. 27.7%; p=0.019) and informational support (37.2% vs. 23.6%; 
p=0.011) irrespective of the presence or lack of support from other alters in the social 
network. The pattern was similar for the seven individual social support indicators 
(Supplemental Table S.5.3.).  
Comparing the composition of ego networks by combinations of a given alter trait 
(e.g. networks where a type of support is reported only from a partner, only from non-
partners, from both partners and non-partners or from neither partners or non-partners) 
revealed significant differences by viral suppression for emotional and informational 
support (Supplemental Table S.5.4.). Comparing HIV status of alters, viral suppression 
was more likely for participants with networks having only HIV-positive alters as the 
source of emotional support (8.3% vs. 4.1%; p=0.05) and less likely if emotional support 
was only available from HIV-negative alters (66.0% vs. 72.6%; p= 0.05). Similarly, viral 
suppression was more likely for participants with network’s having informational support 
from only an HIV-positive alters (9.7% vs. 4.8%; p=0.029) and less likely if 
informational support was only available from HIV-negative alters (59.0% vs. 61.2%; 
p=0.029). Comparing partner status of alters, viral suppression was more likely for 
participants with networks having only a partner as the source of emotional support 
(4.8% vs. 2.0%, p=0.037) and less likely if non-partners were the only source of 
emotional support (55.9% vs. 634.2%; p=0.37). Similarly, viral suppression was more 
likely for participants with networks having informational support from only partners 
(3.4% vs. 2.0; p=0.039) and less likely if non-partners were the only source of 
informational support (50.3% vs. 54.7%; p=0.039). In general, social support was more 
likely available from female compared to male alters and partners compared to non-
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partners, but less so from HIV-positive compared to HIV-negative alters (Supplemental 
Table S.5.5.).  
Since viral suppression was associated with both having an HIV-positive alter and 
partner, we considered these factors jointly. Across all 1004 ego-alter dyads, the 
prevalence of HIV-positive partners was greater among those virally suppressed (5.1% 
vs. 1.6%; p=0.007) and HIV-negative non-partners were marginally more prevalent 
among those with a detectable viral load (Supplemental Table S.5.6.). This pattern was 
also seen at the social network level, viral suppression was more likely among 
participants having an HIV-positive partner and all HIV-negative non-partners (9.7% vs. 
3.4%; p=0.029) or non-partners of any HIV status (17.4% vs. 4.1%; p<0.001) 
(Supplemental Table S.5.7.). In the adjusted model Table 5.5.), there was greater odds of 
viral suppression with each increasing year of age (AOR: 1.04; 95% CI: 1.01, 1.08), 
female sex (AOR: 2.44; 95% CI: 1.42, 4.23) having providers consider patient wishes 
(AOR: 1.86; 95% CI: 1.10, 3.14) and having at least one HIV-positive alter (AOR: 2.02; 
95% CI: 1.12, 3.64).  
 
5.5. Discussion 
This study examined associations with HIV viral suppression among persons 
living with HIV and a history of injection drug use with a focus on the types and sources 
of social support available from their closest network members. Understanding such 
relationships may indicate areas for interventions that focus on individuals and their 
supportive social relations to achieve and maintain viral suppression.  
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The proportion of PWID that were virally suppressed was similar to the overall 
US average (49.5 % vs. 48.4%) (1). We found that having at least one HIV-positive alter 
was associated with viral suppression in the adjusted model. While a greater proportion 
of the virally suppressed had an HIV-positive alter that provided each social support 
indicator or construct, HIV-positive and HIV-negative alters did not differ significantly 
with respect to types of support they were available to provide. Therefore, it may be that 
the source of social support has more impact than the quality of support. Persons living 
with HIV can experience social isolation and little or no social support due to not 
disclosing HIV status out of fear of HIV-related stigma and rejection (27). Unexpectedly, 
our study sample had relatively high levels of social support for a disenfranchised group. 
However, having an HIV-positive alter may provide a trusted and safe source of non-
judgmental support. As an indication of disclosure and support, people living with HIV 
that were comfortable taking their medication in the presence of close friends and with 
emotional and instrumental support available have been found to have higher odds of 
medication adherence (28). Additionally, methadone-maintained persons living with HIV 
having a network member who was aware of their HIV status were nearly three times 
more likely to engage in primary care (29). 
We considered that the HIV positive alters who are most supportive may also be 
partners. Although the HIV-positive alter association may be driven by the HIV-positive 
partner association, it is hard to conclude that there is an effect of having an HIV-positive 
alter who is not a partner because the number in this group was so small. One study found 
that for PWID living with HIV, having a partner in the support network was associated 
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with lower odds of having access to care, measured as seeing the same provider most of 
the time (22). 
Persons who use drugs and are living with HIV face stigma from substance 
misuse and HIV-status jointly (9, 20). Substance use stigma is closely associated with the 
willingness to disclose and fear of social rejection due in part to socially unacceptable 
modes of transmission, particularly among racial minorities (30). Substance use stigma is 
exacerbated by perceptions from providers that persons who use drugs use healthcare 
inefficiently (31). PWID perceiving discrimination from healthcare providers may turn to 
their substance using peers for information about HIV care (32). Although substance use 
was common in this cohort, it was not found to be associated with viral suppression, 
suggesting that patients using substances can be adherent and bias against offering 
treatment due to substance use behaviors should be avoided. However, we did not 
consider the association of the frequency of injection drug use with viral suppression 
among those with current injection drug use. Additionally, there is a need for risk 
reduction interventions given we found that participants with a detectable viral load were 
sharing injection equipment and more likely to engage in condomless sex than persons 
who were virally suppressed. 
Social networks are a resource of social capital that can be mobilized to affect 
positive change on behavior and health (33). Interventions at the network level draw upon 
a number of mechanisms to affect behavior change through social influence (34). Norms 
for medication adherence among PLWH that lead to viral suppression may be influenced 
through peers endorsing and engaging in treatment adherence themselves. Identifying and 
training informal opinion leaders is one means to promote diffusion of such health 
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behaviors (35). More formally trained peer and community health workers have a 
particularly important role in reaching hidden and stigmatized communities, such as 
persons with substance use disorders (36), helping to bridge the cultural divide between 
patients and providers that can result from mistrust of the health care profession among 
disenfranchised groups (Eiser & Ellis, 2007). Our findings indicate that there is an 
opportunity to intervene with HIV-positive peers and partners to promote behaviors that 
support medication adherence and ultimately viral suppression. 
Viral suppression was positively associated with having wishes considered by the 
provider. Persons who use drugs experience barriers to care related to difficulty 
communicating with medical providers and lack of knowledge about how and where to 
access care (32). However, patient-provider relationships that include information 
sharing, shared decision making and respect for patients’ decisions have been associated 
with greater odds of medication adherence (37) and clinic attendance has been associated 
with the quality of provider communication (27), patient-provider relationships (20) and 
clarity of medical instructions (38). 
 
5.6. Limitations 
Limitations of the study include cross-sectional data from a single study visit that 
does not allow examination of the lag that may exist between social network exposures 
and viral suppression outcomes over time, limiting the ability to draw causal associations 
from these results. Because most exposures evaluated were self-reported, social 
desirability and recall bias may be a factor, particularly for ART use and reasons for 
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stopping ART medication. We did not have the data to examine concerns for medication 
adherence in depth. Because social support was high overall, there may be associations 
with types of social support and viral suppression that might be identified in networks 
more broadly defined beyond the most important members. Given the high level of 
engagement in HIV care in this population, results may not extrapolate to groups with a 
lower prevalence of retention in care typical of PWID in general.  
 
5.7. Conclusions 
Having network members who are HIV-positive was associated with viral 
suppression. Although additional data are needed to understand the reason for this 
association, it may be related to the positive influence of disclosure of HIV status to a 
peer and receiving support from persons who share the experience of living with HIV. 
Future research should explore the role of having an HIV-positive partner in particular 
and the ability of partner-focused interventions to improve health outcomes among 
PWID. The greater prevalence of condomless vaginal sex among persons with a 
detectable viral load is a concern and warrants further investigation. In addition, findings 
suggest the importance of healthcare providers promoting shared decision making with 
their patients living with HIV and a history of injection drug use in order to achieve a 
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Table 5.1. Participant characteristics by viral suppression. 
 Total HIV viral load≥50 
HIV viral 
load<50  
 N=293 N=148 N=145  
Characteristic N (%) N (%) N (%) p-value 
Age, median (IQR) 56 (51-60) 56 (50-60) 56 (52-61) 0.11 
Female 98 (33.4) 39 (26.4) 59 (40.7) 0.009 
Men who have sex with men 31 (10.7) 16 (11.0) 15 (10.4) 0.87 
Health insurance 1 289 (98.6) 145 (98.0) 144 (99.3) 0.32 
Homelessness 1 17 (5.8) 11 (7.4) 6 (4.1) 0.23 
Income <5,000 1 195 (66.8) 97 (66.0) 98 (67.6) 0.77 
 
Substance use 
    
Injection drug use, any 2 91 (31.1) 49 (33.1) 42 (29.0) 0.44 
Inject heroin alone 1 35 (11.9) 21 (14.2) 14 (9.7) 0.23 
Inject cocaine alone 1 25 (8.5) 14 (9.5) 11 (7.6) 0.57 
Inject speedball 1 43 (14.7) 23 (15.5) 20 (13.8) 0.67 
Frequency of injection    0.49 
None 222 (76.0) 108 (73.5) 114 (78.6)   
<Daily 39 (13.4) 23 (15.6) 16 (11.0)   
Daily 31 (10.6) 16 (10.9) 15 (10.3)   
Crack cocaine 1 76 (25.9) 44 (29.7) 32 (22.1) 0.13 
Non-injection drug misuse 1 111 (37.9) 63 (42.6) 48 (33.1) 0.095 
Opioid replacement therapy 1 135 (46.1) 72 (48.6) 63 (43.4) 0.37 
Substance use support group 1 141 (48.1) 65 (43.9) 76 (52.4) 0.15 
 
Transmission risk 3 
    
Shared injection equipment 1 16 (23) 10 (26) 6 (19) 0.53 
Condomless anal sex 1 9 (43) 4 (57) 5 (36) 0.35 
Condomless vaginal sex 1 73 (64.0) 40 (72.7) 33 (55.9) 0.062 
 
Health status 
    
≥3 comorbidities (not HIV) 4 55 (18.8) 25 (16.9) 30 (20.7) 0.41 
Hepatitis C infection 5 181 (62.2) 92 (62.6) 89 (61.8) 0.89 
CESD>22 1,6 67 (22.9) 35 (23.6) 32 (22.1) 0.75 
Ever psychiatric diagnosis 150 (51.2) 74 (50.0) 76 (52.4) 0.68 
CD4 T-Cells 1     0.74 
<200 21 (14.9) 9 (14.8) 12 (15.0)   
200-499 46 (32.6) 22 (36.1) 24 (30.0)   
≥500 74 (52.5) 30 (49.2) 44 (55.0)   
HIV viral load<50 prior visit 197 (69.6) 80 (56.3) 117 (83.0) <0.001 
HIV viral load<50 next visit 166 (63.4) 51 (39.2) 115 (87.1) <0.001 
 
HIV knowledge 
    
Goal: viral load to go down 208 (71.5) 103 (70.5) 105 (72.4) 0.72 




Table 5.1. continued 
 Total HIV viral load≥50 
HIV viral 
load<50  
 N=293 N=148 N=145  
Characteristic N (%) N (%) N (%) p-value 
Healthcare use     
Antiretroviral treatment 1 247 (84.6) 125 (85.0) 122 (84.1) 0.83 
HIV provider visit/6 months 266 (96.4) 131 (95.6) 135 (97.1) 0.50 
Know HIV provider ≥2 years 186 (67.6) 90 (66.2) 96 (69.1) 0.61 
≥1 ED visit 1 86 (29.5) 47 (32.0) 39 (26.9) 0.34 
≥1 hospital admission 1 57 (19.5) 36 (24.3) 21 (14.5) 0.033 
Provider considers wishes 187 (64.5) 84 (57.5) 103 (71.5) 0.013 
Doctors explain clearly 198 (67.8) 98 (66.7) 100 (69.0) 0.67 
IQR=interquartile range 
1 Over prior 6 months  
2 Over prior 12 months 
3 21 responded to the question about condom use and anal sex and 114 about condom use 
and vaginal sex. 
4 Diabetes mellitus, hypertension, heart disease, stroke, renal disease, respiratory disease, 
seizure disorder, dyslipidemia 
5 Detectable Hepatitis C RNA 




Table 5.2. Barriers to healthcare and antiretroviral medication use by viral 
suppression.  
 Total HIV viral load≥50 
HIV viral 
load<50  
 N=293 N=148 N=145  
 N (%) N (%) N (%) p-value 
Barrier to care 1     
No reliable transportation 105 (35.8) 57 (38.5) 48 (33.1) 0.33 
Unstable housing 54 (18.5) 26 (17.6) 28 (19.4) 0.68 
Can’t afford care 35 (11.9) 17 (11.5) 18 (12.4) 0.81 
Drug use makes it hard 25 (8.5) 14 (9.5) 11 (7.6) 0.57 
Don’t want to disclose drug use 21 (7.2) 8 (5.4) 13 (9.0) 0.24 
Don’t trust medical system 14 (4.8) 7 (4.7) 7 (4.8) 0.97 
Wait too long for appointments 15 (5.1) 8 (5.4) 7 (4.8) 0.82 
Wait too long at clinic 20 (6.8) 10 (6.8) 10 (6.9) 0.96 
Inconvenient appointments 22 (7.5) 13 (8.8) 9 (6.2) 0.40 
 
Reason for stopping ART 2 
    
Too many pills 34 (30.9) 17 (32.7) 17 (29.3) 0.70 
Don’t know why 26 (23.6) 8 (15.4) 18 (31.0) 0.054 
Other reason 22 (20.0) 11 (21.2) 11 (19.0) 0.77 
Side effects 15 (13.6) 7 (13.5) 8 (13.8) 0.96 
Nonadherence 10 (9.1) 6 (11.5) 4 (6.9) 0.40 
Viral resistance/treatment failure 6 (5.5) 2 (3.8) 4 (6.9) 0.48 
Drug interactions 5 (4.5) 1 (1.9) 4 (6.9) 0.21 
ART=Antiretroviral treatment 
1 Not a problem vs. somewhat-major problem 




Table 5.3. Social network characteristics by viral suppression. 
 
Total HIV viral load≥50 
HIV viral 
load<50  
 N=293 N=148 N=145  
Characteristic N (%) N (%) N (%) p-value 
Network size, median (IQR) 3 (2-5) 3 (2-5) 4 (3-5) 0.010 
Age, median (IQR) 51 (44-57) 50 (44-57) 52 (46-57) 0.19 
     
One or more alters     
Female  276 (94.5) 139 (94.6) 137 (94.5) 0.98 
Ever IDU 97 (36.3) 49 (36.8) 48 (35.8) 0.86 
HIV-positive  74 (25.8) 28 (19.4) 46 (32.2) 0.014 
Partner/spouse 107 (36.5) 45 (30.4) 62 (42.8) 0.028 
HIV-positive partner 31 (10.6) 6 (4.1) 25 (17.2) <0.001 
Relative  257 (87.7) 132 (89.2) 125 (86.2) 0.44 
Years known, median (IQR) 34 (24-43) 34 (25-43) 33 (23-44) 0.70 
Talk with daily  250 (85.3) 124 (83.8) 126 (86.9) 0.45 
Frequently-always argue 90 (30.7) 46 (31.1) 44 (30.3) 0.89 
Regularly goes to clinic 1 178 (97.3) 79 (96.3) 99 (98.0) 0.49 
Helps you understand HIV 189 (69.7) 94 (69.1) 95 (70.4) 0.82 
HIV-positive in HIV care 2 71 (99) 26 (100) 45 (98) 0.45 
HIV-positive talk about HIV care 2 53 (74) 17 (65) 36 (78) 0.23 
IQR=interquartile range 
1 If alter has a chronic health condition  










 n=293 n=148 n=145  
Social support N (%) N (%) N (%) p-value 
Emotional 1     
Any alter 273 (93.2) 134 (90.5) 139 (95.9) 0.071 
HIV-positive 65 (22.4) 24 (16.4) 41 (28.5) 0.014 
Partner 97 (33.1) 39 (26.4) 58 (40.0) 0.013 
Female 249 (85.3) 124 (84.4) 125 (86.2) 0.66 






Any alter 266 (90.8) 130 (87.8) 136 (93.8) 0.078 
HIV-positive 64 (22.1) 24 (16.4) 40 (27.8) 0.020 
Partner 100 (34.1) 41 (27.7) 59 (40.7) 0.019 
Female 248 (84.6) 122 (82.4) 126 (86.9) 0.29 
Injection drug use, ever 80 (28.9) 38 (27.5) 42 (30.2) 0.62 
 
Informational 1  
  
 
Any alter 243 (82.9) 116 (78.4) 127 (87.6) 0.036 
HIV-positive 61 (21.0) 22 (15.0) 39 (27.1) 0.011 
Partner 89 (30.4) 35 (23.6) 54 (37.2) 0.011 
Female 225 (76.8) 109 (73.6) 116 (80.0) 0.20 
Injection drug use, ever 78 (28.2) 37 (26.6) 41 (29.7) 0.57 





Table 5.5. Correlates of viral suppression. 
 Bivariate  Multivariable  
 HIV viral 
load<50 
 HIV viral 
load<50 
 
 OR (CI) p-value AOR (CI) p-value 
Ego characteristic     
Age, years 1.03 (0.99, 1.06) 0.125 1.04 (1.01, 1.08) 0.025 
Female 1.92 (1.17, 3.14) 0.010 2.44 (1.42, 4.23) 0.001 
Homelessness 0.54 (0.19, 1.49) 
 
0.234   
Injection drug use 0.82 (0.50, 1.35) 0.444   
Crack use 0.67 (0.39, 1.13) 0.136   
Street drugs, non-injection 0.67 (0.42, 1.07) 0.096   
Substance/alcohol support 
group 
1.43 (0.90, 2.26) 0.129   
CESD>22 0.91 (0.53, 1.58) 0.748   
Ever any psychiatric diagnosis 1.10 (0.70, 1.74) 0.679   
Hepatitis C infection 0.97 (0.60, 1.55) 0.891   
≥3 comorbidities (not HIV) 1.28 (0.71, 2.31) 0.406   
≥1 ED visit 0.78 (0.47, 1.30) 0.342   
My wishes are considered by 
my provider 
1.85 (1.14, 3.02) 0.013 1.86 (1.10, 3.14) 0.021 
Doctors explain things in a 
clear way 
1.04 (0.81, 1.34) 0.750   
Lack transportation 0.79 (0.49, 1.28) 0.335   
Wait too long at clinic 
 
1.02 (0.41, 2.53) 0.962   
Social network     
Network size>3 1.41 (0.89, 2.23) 0.145   
Alter age, mean years 1.01 (0.99, 1.04) 0.322   
Female alters, number 1.20 (0.98, 1.48) 0.078   
Partner/spouse 1 1.71 (1.06, 2.76) 0.029 1.48 (0.88, 2.50) 0.137 
Relatives, number 1.06 (0.90, 1.23) 0.489   
HIV-positive 1 
 
1.96 (1.14, 3.38) 0.015 2.02 (1.12, 3.64) 0.019 
Social support constructs 1, 2     
Emotional support  2.42 (0.90, 6.48) 0.079   
Instrumental support  2.09 (0.91, 4.82) 0.083   
Informational support 1.95 (1.04, 3.65) 0.038 1.48 (0.74, 2.95) 0.265 
All support constructs 2.61 (0.98, 6.93) 0.054   
Intensity of support     
Moderate 1    
High 1.66 (0.89, 3.10) 0.109   
Very high 1.65 (0.92, 2.99) 0.097   
OR=odds ratio; AOR=adjusted odds ratio; CI=confidence interval 
1 ≥1 network members with given characteristic 
2  Network member always provides at least one indicator for each construct  
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Table S.5.1. Self-reported antiretroviral medications used in the prior six months. 
Medication 1 Class N (%) 
Regimen 1   
Recommended initial regimen  INSTI + 2 NRTIs 71 (26.9) 
Recommended in certain clinical situations Boosted PI + 2 NRTIs 44 (16.7) 
 NNRTI + 2 NRTIs 32 (12.1) 
 INSTI + 2 NRTIs 26 (9.8) 
Other combinations of antiretroviral medications Various 91 (34.5) 
 
Individual medication formulations   
Ritonavir PI 97 (14.2) 
Emtricitabine / Tenofovir DF NRTI 85 (12.4) 
Darunavir PI 74 (10.8) 
Dolutegravir INSTI 51 (7.5) 
Raltegravir INSTI 42 (6.1) 
Abacavir / Dolutegravir / Lamivudine 2 NRTI / INSTI  36 (5.3) 
Abacavir / Lamivudine NRTI 33 (4.8) 
Unknown NA 32 (4.7) 
Efavirenz / Emtricitabine / Tenofovir DF 2 NNRTI / NRTI 30 (4.4) 
Atazanavir PI 29 (4.2) 
Elvitegravir / Cobi / Emtricitabine / Tenofovir DF 2 INSTI / NRTI 19 (2.8) 
Elvitegravir / Cobi / Emtricitabine / Tenofovir AF 2 INSTI / NRTI 19 (2.8) 
Lipinavir / ritonavir PI 17 (2.5) 
Darunavir / Cobicistat PI / booster 17 (2.5) 
Lamivudine NRTI 15 (2.2) 
Emtricitabine / Tenofovir AF NRTI 13 (1.9) 
Etravirine NNRTI 12 (1.8) 
Rilpiverine / Emtricitabine / Tenofovir DF 2 NNRTI / NRTI 10 (1.5) 
Other Various 54 (7.9) 
Data from 264 of 268 participants reporting ART use.  
PI= Protease Inhibitor; NRTI= Nucleoside Reverse Transcriptase Inhibitors; Non-
Nucleoside Reverse Transcriptase Inhibitors; INSTI=Integrase Strand Transfer Inhibitor 
Antiretroviral treatment reported by 264 participants 
1 Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with 
HIV 





Table S.5.2. Self-reported chronic comorbidities by viral suppression.  
 Total HIV viral load≥50 
HIV viral 
load<50  
 n=293 n=148 n=145  
Comorbidity N (%) N (%) N (%) p-value 
Number of comorbidities 1    0.66 
0 83 (28.3) 40 (27.0) 43 (29.7)  
1 89 (30.4) 46 (31.1) 43 (29.7)  
2 66 (22.5) 37 (25.0) 29 (20.0)  
≥3 55 (18.8) 25 (16.9) 30 (20.7)  
Hypertension 144 (49.1) 73 (49.3) 71 (49.0) 0.95 
Chronic lung disease (asthma, 
COPD, emphysema, not 
pneumonia) 
70 (23.9) 34 (23.0) 36 (24.8) 0.71 
High cholesterol 67 (22.9) 34 (23.0) 33 (22.8) 0.97 
Diabetes (high blood sugar) 43 (14.7) 19 (12.8) 24 (16.6) 0.37 
Heart problem (angina, heart 
attack, CHF) 34 (11.6) 18 (12.2) 16 (11.0) 0.76 
Stroke (CVA) 28 (9.6) 12 (8.1) 16 (11.0) 0.39 
Renal disease or failure 19 (6.5) 10 (6.8) 9 (6.2) 0.85 
Seizures (epilepsy, convulsions) 15 (5.1) 8 (5.4) 7 (4.8) 0.82 
 
Psychiatric comorbidities     
Depression 145 (49.5) 72 (48.6) 73 (50.3) 0.77 
Bipolar (manic depression) 75 (25.6) 34 (23.0) 41 (28.3) 0.30 
Anxiety/panic 58 (19.8) 31 (20.9) 27 (18.6) 0.62 
Schizophrenia/ Schizoaffective 
disorder 11 (3.8) 3 (2.0) 8 (5.5) 0.12 
COPD= Chronic obstructive pulmonary disease; CHF=Congestive heart failure; 
CVA=Cerebrovascular accident 













 N=293 N=148 N=145  
Social support 1 N (%) N (%) N (%) p-value 
Intensity of support    0.19 
Moderate 70 (24.1) 42 (28.6) 28 (19.4)  
High 97 (33.3) 46 (31.3) 51 (35.4)  
Very High 
 
124 (42.6) 59 (40.1) 65 (45.1) 
 
Emotional support     
Could talk to if down    
Any alter 239 (81.6) 119 (80.4) 120 (82.8) 0.60 
HIV-positive 53 (18.2) 17 (11.6) 36 (24.8) 0.004 
Partner 85 (29.0) 35 (23.6) 50 (34.5) 0.041 
Female 213 (72.9) 107 (72.8) 106 (73.1) 0.95 
Injection drug use, ever 69 (24.7) 32 (23.0) 37 (26.4) 0.51 
 
Would say is in your corner 
  
 
Any alter 260 (89.3) 125 (85.6) 135 (93.1) 0.038 
HIV-positive 61 (21.0) 22 (15.1) 39 (27.1) 0.012 
Partner 90 (30.7) 36 (24.3) 54 (37.2) 0.017 
Female 234 (80.4) 115 (78.8) 119 (82.1) 0.48 






Would pitch in to help do things    
Any 246 (84.2) 119 (81.0) 127 (87.6) 0.12 
HIV-positive 57 (19.6) 21 (14.3) 36 (25.0) 0.021 
Partner 88 (30.0) 36 (24.3) 52 (35.9) 0.031 
Female 226 (77.1) 111 (75.0) 115 (79.3) 0.38 
Injection drug use, ever 69 (24.7) 32 (22.9) 37 (26.6) 0.47 
 
Would loan over $25 
  
 
Any alter 236 (80.8) 112 (76.2) 124 (85.5) 0.043 
HIV-positive 59 (20.2) 22 (15.0) 37 (25.5) 0.025 
Partner 85 (29.0) 34 (23.0) 51 (35.2) 0.021 
Female 214 (73.3) 104 (70.7) 110 (75.9) 0.32 
Injection drug use, ever 64 (22.5) 28 (19.4) 36 (25.7) 0.21 
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 N=293 N=148 N=145  
Social support 1 N (%) N (%) N (%) p-value 
Would let stay if needed a place    
Any alter 245 (83.6) 120 (81.1) 125 (86.2) 0.24 
HIV-positive 59 (20.3) 21 (14.4) 38 (26.2) 0.012 
Partner 90 (30.7) 35 (23.6) 55 (37.9) 0.008 
Female 226 (77.1) 112 (75.7) 114 (78.6) 0.55 






Someone to give situation advice    
Any alter 233 (79.5) 111 (75.0) 122 (84.1) 0.053 
HIV-positive 56 (19.2) 20 (13.6) 36 (25.0) 0.014 
Partner 85 (29.0) 32 (21.6) 53 (36.6) 0.005 
Female 213 (72.7) 104 (70.3) 109 (75.2) 0.35 
Injection drug use, ever 71 (25.5) 33 (23.6) 38 (27.5) 0.45 
     
Does help understand health    
Any alter 204 (69.6) 98 (66.2) 106 (73.1) 0.20 
HIV-positive 53 (18.2) 18 (12.2) 35 (24.1) 0.008 
Partner 74 (25.3) 27 (18.2) 47 (32.4) 0.005 
Female 184 (62.8) 89 (60.1) 95 (65.5) 0.34 
Injection drug use, ever 63 (22.1) 29 (20.3) 34 (23.9) 0.46 




Table S.5.4. Frequency of support available within networks having at least one type 
of alter by viral suppression. 





 n=293 n=148 n=145  
Social support construct N (%) N (%) N (%) p-value 
Emotional     
HIV-positive HIV-negative    0.050 
Yes Yes 47 (16.2) 18 (12.3) 29 (20.1)  
Yes No 18 (6.2) 6 (4.1) 12 (8.3)  
No Yes 201 (69.3) 106 (72.6) 95 (66.0)  
No No 24 (8.3) 16 (11.0) 8 (5.6)  
Partner Non-partner    0.037 
Yes Yes 87 (29.7) 36 (24.3) 51 (35.2)  
Yes No 10 (3.4) 3 (2.0) 7 (4.8)  
No Yes 176 (60.1) 95 (64.2) 81 (55.9)  
No No 20 (6.8) 14 (9.5) 6 (4.1)  
Female Male    0.17 
Yes Yes 169 (57.9) 81 (55.1) 88 (60.7)  
Yes No 80 (27.4) 43 (29.3) 37 (25.5)  
No Yes 23 (7.9) 9 (6.1) 14 (9.7)  
No No 20 (6.8) 14 (9.5) 6 (4.1)  
Ever inject  Never inject     0.17 
Yes Yes 68 (24.9) 30 (22.1) 38 (27.7)  
Yes No 13 (4.8) 7 (5.1) 6 (4.4)  
No Yes 166 (60.8) 81 (59.6) 85 (62.0)  
No No 26 (9.5) 18 (13.2) 8 (5.8)  
Instrumental     
HIV-positive HIV-negative    0.061 
Yes Yes 46 (15.9) 18 (12.3) 28 (19.4)  
Yes No 18 (6.2) 6 (4.1) 12 (8.3)  
No Yes 197 (67.9) 103 (70.5) 94 (65.3)  
No No 29 (10.0) 19 (13.0) 10 (6.9)  
Partner Non-partner    0.069 
Yes Yes 93 (31.7) 38 (25.7) 55 (37.9)  
Yes No 7 (2.4) 3 (2.0) 4 (2.8)  
No Yes 166 (56.7) 89 (60.1) 77 (53.1)  
No No 27 (9.2) 18 (12.2) 9 (6.2)  
Female Male    0.24 
Yes Yes 168 (57.3) 79 (53.4) 89 (61.4)  
Yes No 80 (27.3) 43 (29.1) 37 (25.5)  
No Yes 18 (6.1) 8 (5.4) 10 (6.9)  




Table S.5.4. continued 






  n=293 n=148 n=145  
Social support construct N (%) N (%) N (%) p-value 
Instrumental     
Ever inject  Never inject     0.13 
Yes Yes 70 (25.3) 32 (23.2) 38 (27.3)  
Yes No 10 (3.6) 6 (4.3) 4 (2.9)  
No Yes 163 (58.8) 77 (55.8) 86 (61.9)  
No No 34 (12.3) 23 (16.7) 11 (7.9)  
Informational     
HIV-positive HIV-negative    0.029 
Yes Yes 40 (13.7) 15 (10.2) 25 (17.4)  
Yes No 21 (7.2) 7 (4.8) 14 (9.7)  
No Yes 175 (60.1) 90 (61.2) 85 (59.0)  
No No 55 (18.9) 35 (23.8) 20 (13.9)  
Partner Non-partner    0.039 
Yes Yes 81 (27.6) 32 (21.6) 49 (33.8)  
Yes No 8 (2.7) 3 (2.0) 5 (3.4)  
No Yes 154 (52.6) 81 (54.7) 73 (50.3)  
No No 50 (17.1) 32 (21.6) 18 (12.4)  
Female Male    0.094 
Yes Yes 143 (48.8) 65 (43.9) 78 (53.8)  
Yes No 82 (28.0) 44 (29.7) 38 (26.2)  
No Yes 18 (6.1) 7 (4.7) 11 (7.6)  
No No 50 (17.1) 32 (21.6) 18 (12.4)  
Ever inject  Never inject     0.12 
Yes Yes 65 (23.5) 30 (21.6) 35 (25.4)  
Yes No 13 (4.7) 7 (5.0) 6 (4.3)  
No Yes 143 (51.6) 66 (47.5) 77 (55.8)  
No No 56 (20.2) 36 (25.9) 20 (14.5)  
1 ≥1 alters always available to provide support for each support construct derived by 





Table S.5.5. Frequency of support available from sources of support for all dyads. 
 HIV-positive 1  Partner 1 







Social support N (%) N (%) p-value  N (%) N (%) p-value 
Indicators 1        
Could talk to if down 580 (70.2) 64 (60.4) 0.039  597 (66.8) 87 (79.1) 0.009 
Would say is in your corner 664 (81.3) 79 (74.5) 0.099  698 (78.9) 92 (83.6) 0.24 
Would pitch in to help do things 604 (73.6) 70 (66.0) 0.10  625 (70.3) 91 (82.7) 0.006 
Would loan more than $25 568 (68.9) 74 (69.8) 0.85  588 (65.9) 88 (80.0) 0.003 
Would let stay if needed a place 609 (73.7) 78 (73.6) 0.97  633 (70.8) 93 (84.5) 0.002 
Someone to give situation advice 579 (70.1) 74 (69.8) 0.95  606 (67.8) 88 (80.0) 0.009 
Does help understand health 475 (57.6) 69 (65.1) 0.14  490 (54.9) 77 (70.0) 0.003 
 
Constructs 2 
       
Emotional  704 (85.7) 84 (79.2) 0.078  744 (83.7) 99 (90.0) 0.085 
Informational  702 (85.0) 87 (82.1) 0.43  735 (82.2) 103 (93.6) 0.002 
Instrumental  613 (74.3) 82 (77.4) 0.50  646 (72.3) 92 (83.6) 0.011 
p values adjusted for clustering on ego  
Non-missing data: 932 for HIV status; 1004 for partner status 
1 Alter always provides support for given indicator 
2 Alter always provides support for at least one indicator by support construct 
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Table S.5.5. continued.  
 Female 1  Injection drug use 1 





Yes n=139  
Social support N (%) N (%) p-value  N (%) N (%) p-value 
Indicators 2        
Could talk to if down 245 (61.9) 438 (72.3) <0.001  514 (69.7) 91 (65.5) 0.32 
Would say is in your corner 304 (77.6) 485 (80.7) 0.23  596 (81.3) 99 (73.3) 0.033 
Would pitch in to help do things 261 (66.2) 455 (75.5) 0.002  539 (73.6) 96 (69.1) 0.27 
Would loan more than $25 256 (64.6) 420 (69.5) 0.11  520 (70.7) 89 (64.0) 0.11 
Would let stay if needed a place 265 (66.9) 461 (76.1) 0.002  561 (76.1) 92 (66.2) 0.014 
Someone to give situation advice 259 (65.4) 435 (71.8) 0.032  513 (69.6) 96 (69.1) 0.90 
Does help understand health 201 (50.8) 366 (60.5) 0.002  415 (56.3) 85 (61.2) 0.29 
 
Constructs 3 
       
Emotional  321 (81.9) 521 (86.1) 0.072  630 (85.7) 108 (78.8) 0.040 
Informational  315 (79.5) 523 (86.3) 0.005  634 (86.0) 111 (79.9) 0.061 
Instrumental  274 (69.2) 464 (76.7) 0.008  540 (73.3) 107 (77.0) 0.36 
p values adjusted for clustering on ego  
1 Non-missing data: 1,002 for gender; 876 for IDU status 
2 Alter always provides support for given indicator 
3 Alter always provides support for at least one indicator by support construct 
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Table S.5.6. Frequency of types of alters by viral suppression for all dyads. 





Dyad level N=1004 N=479 N=525 p-
value 
Non-partner, HIV-negative 752 (80.7) 372 (83.4) 380 (78.2) 0.007 
Partner, HIV-positive 32 (3.4) 7 (1.6) 25 (5.1)  
Partner, HIV-negative 74 (7.9) 38 (8.5) 36 (7.4)  
Non-partner, HIV-positive 74 (7.9) 29 (6.5) 45 (9.3)  
p-value adjusted for clustering on ego  
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Table S.5.7. Network composition for combinations of alter HIV and partner status by viral suppression. 
  
Non-partner 
Total VL>=50 VL<50  
  N=293 N=148 N=145  
Effect Partner N (%) N (%) N (%) p-value 
HIV-pos. alter Any positive* 74 (25.8) 28 (19.4) 46 (32.2) 0.014 
 All negative 211 (74.0) 115 (80.4) 96 (67.6)  
Partner Any partner 107 (36.5) 45 (30.4) 62 (42.8) 0.028 
 No partners 184 (63.2) 102 (69.4) 82 (56.9)  
HIV-pos. partner + all – 19 (6.5) 5 (3.4) 14 (9.7) 0.029 
 + +/– 31 (10.6) 6 (4.1) 25 (17.2) <0.001 
HIV-pos. non-partner – any + 43 (14.8) 22 (15.0) 21 (14.6) 0.93 
 +/– any + 55 (18.8) 23 (15.5) 32 (22.1) 0.15 
HIV-neg. partner – all – 67 (23.4) 36 (25.0) 31 (21.8) 0.55 
 +/– all – 219 (78.8) 116 (83.5) 103 (74.1) 0.057 
– HIV-negative; + HIV-positive 
*HIV-negative partner with either HIV-positive/-negative non-partner is similar given that there is only one network that consists of 
only one alter and that alter is an HIV-positive partner; therefore, all networks that have at least one HIV-positive alter include cases 
where partners are HIV-negative. 
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6. Conclusion  
 
6.1. Summary of findings  
Persons who inject drugs experience a number of health-related disparities, 
including greater risk for HIV infection and barriers in accessing preventative care (1, 2). 
At the national level, research funding priorities include eliminating disparities in the 
continuum of care for persons who use substances (3), policies to increase the number of 
persons living with HIV that are virally suppressed (4) and incentives to promote more 
optimal use of healthcare resources (5). While social networks are known to influence 
healthcare seeking and health outcomes (6), most studies of the social networks of PWID 
have not examined the most important, closest ties, which may be the most influential for 
behavior change (7, 8). 
The goal of this study was to increase our understanding of the factors that can 
influence suboptimal use of healthcare services and HIV viral suppression among PWID 
by examining the closest social network ties. A more comprehensive understanding of the 
influence of social networks in healthcare seeking behaviors and outcomes can help to 
identify important patient, social network and community level opportunities for 
intervention to support HIV viral suppression and avoid potentially preventable use of 
costly ED services. Results add to the evidence regarding social network factors related 
to disparities in care and health outcomes for a difficult to reach population — persons 
who inject drugs and are living with or at risk for HIV. 
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The thread that links findings of the three analyses in this sample of PWID with 
high levels of social support regardless of current or former injection drug use, is that 
both the source and quality of support is associated with healthcare utilization and health 
outcomes. For example, partners were more likely to be perceived as always available for 
six to seven domains of support, the greatest of any relationship type, and having high 
frequency ED visits was less likely for participants who had a partner. In addition, 
persons having HIV-positive alters, including HIV-positive partners, were more likely to 
be virally suppressed, despite no differences with respect to the level of support available 
from HIV-positive and HIV-negative alters having been identified. In terms of the quality 
of support, informational support was found to be associated with a lower likelihood of 
having an ED visit, the only support type to be associated with either outcome examined 
in this study. Thus, peers living with HIV, partners and the availability of informational 
support from close social ties represent opportunities for interventions aimed to address 
health disparities among PWID. 
In aim 1 we developed and implemented a social network survey to determine 
types of support and differences by time since last injection drug use. There were high 
levels of support overall: 1) Moderate support; 2) High support; and 3) Very high 
support. The odds of membership in the very high class was lower compared to the 
moderate support class for participants with non-injection drug use in the past year. The 
key social network factor associated with latent support was a lower odds of very high 
support compared to moderate support with each additional network member who ever 
injected drugs, demonstrating that a lower intensity of social support is available from 
peers with a history of injection drug use. 
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In aim 2, we determined social network factors associated with frequent 
emergency department use. Compared to no ED visits in the prior six months, the odds of 
having one visit were lower for participants having informational support and the odds of 
two or more visits were lower for participants having a partner. This finding suggests that 
information from peers may play a role in decisions about seeking emergency services 
and that partners may provide support that addresses the barriers to care experienced by 
PWID.  
In aim 3, we determined social network factors associated with HIV viral 
suppression. For the 293 PWID living with HIV, the odds of HIV viral suppression were 
greater for participants having at least one HIV-positive alter. This finding indicates that 
homophily between individuals and their network members of an often-stigmatized 
health condition may be supportive of health-related behaviors. We additionally 
confirmed the importance of shared decision-making between HIV care providers and 
their patients. 
 
6.2. Strengths and limitations  
These findings can provide insight into the role of social networks on HIV care 
and clinical outcomes as well as optimizing use of health care resources to avoid 
potentially preventable ED visits. Our focus on the very closest and potentially most 
influential networks ties is unique and suggests opportunities to intervene with peers of 
individuals that face barriers to care related to the stigmatized nature of injection drug use 
as well as HIV infection. 
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Limitations include misperceptions or lack of awareness regarding alter attitudes 
and behaviors, differential recall bias, social desirability bias and confounding by 
unknown variables. ALIVE participants may be subject to the Hawthorne effect, where 
study participants benefit from increased care and follow up and exhibit behavior change 
from being under observation (9). Additionally, persons agreeing to participate in the 
ALIVE study may have higher levels of retention in care than is typical for PWID. 
Consequently, they may not be similar to other groups of PWID. Missing information or 
misclassification may occur due to respondent fatigue, forgetting or refusal to respond 
out of privacy concerns for their network members. Despite these limitations, study 
findings contribute to the literature regarding the social networks of PWID with our focus 
on the closest social ties and also suggest directions for future research in addressing 
disparities in health experienced by PWID. 
 
6.3. Public health implications and recommendations for future research  
Finding more effective means of promoting the health and optimal use of 
healthcare services among PWID outside of the clinical setting is critical given the 
structural and psychosocial barriers that hinder health promoting and healthcare seeking 
behaviors. Interventions that leverage the social resources available to PWID to achieve 
and maintain viral suppression can not only prevent disease progression, but also 
population level HIV transmission. Given the concerns about the increasing cost of 
healthcare and limited resources, the social networks of PWID also represent an 
opportunity to encourage use of preventative care that can potentially avoid costly and 
inefficient use of emergency services.  
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Further investigation of social network factors associated with health outcomes 
and healthcare use is warranted. In particular, it is essential to understand how social 
support may influence retention in HIV care and adherence to antiretroviral medication. 
Given the association of HIV-positive alters with viral suppression among PWID in this 
sample, it would be helpful to understand what aspect of their relationships may be 
influential, particularly focusing on the roles of social influence through modeling self-
care and the potential for support from someone with a shared experience to mediate 
community-level HIV stigma and individual shame regarding their diagnosis. To better 
understand how peers may influence use of healthcare resources, research should focus 
on what health-related information is being communicated and which healthcare seeking 
behaviors are being modeled by peers. While having a partner is not a universal social 
asset, it is important to explore what partner traits and behaviors promote optimal 
healthcare seeking, both for prevention and emergency care, and which barriers partners 
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